

Potential Herb-Drug Interactions for Commonly Used Herbs**

How to Read the Chart

The chart is read from left to right. The information in the Basis of Concern column provides the evidence for the information in the Potential Interaction column. For example, *clinical studies* found that administration of St John's wort resulted in *decreased levels* of cancer chemotherapeutic drugs. (Italicized words represent the information in the Herb-Drug Interaction chart below.)

More details may be provided in the Basis of Concern column. For example, in a *clinical study with healthy volunteers* administration of St John's wort resulted in *increased clearance* of the hypoglycemic drug gliclazide, and so may *reduce the drug's efficacy*, however, *glucose and insulin response to glucose loading were unchanged*.

A recommended action is suggested on a risk assessment of the information in the Basis of Concern. In these examples:

- It is recommended that St John's wort is contraindicated in patients taking cancer chemotherapeutic drugs.
- In the case of gliclazide, because the trial found little effect on a clinically-relevant outcome, the potential interaction is considered low risk and a caution is recommended: the patient should be monitored, through the normal process of repeat consultations.

For more information on the process used to assess the herb-drug interaction research (and why some research is not included), how the risk of interaction is assessed, with worked examples from the chart: go to www.mediherb.com and view the Herb-Drug Interaction Chart under 'Resources'.

Health care professionals please note: when a patient presents using any of the drugs listed below and there is a potential interaction with the herb you intend to dispense, it is important that you or your patient discuss the potential interaction with their prescribing physician before you dispense the herb to the patient.

Drug	Potential Interaction	Basis of Concern	Recommended Action
Bilberry <i>Vaccinium myrtillus</i>			
Warfarin	Potential of bleeding.	Herb Alone Antiplatelet activity observed in healthy volunteers (173 mg/day of bilberry anthocyanins). ¹ Case report of postoperative bleeding (bilberry extract undefined). ² Herb or Constituent and Drug Uncontrolled trial (600 mg/day of bilberry anthocyanins + 30 mg/day of vitamin C for 2 months then reduced maintenance dose) of 9 patients taking anticoagulant drugs – treatment reduced retinal hemorrhages without impairing coagulation. ³ Case report (patient reported to consume “large amounts of bilberry fruits every day for five years”). ⁴	Monitor at high doses (> 100 mg/day anthocyanins, low level of risk).
Black Cohosh <i>Actaea racemosa</i> (<i>Cimicifuga racemosa</i>)			
Statin drugs eg atorvastatin	May potentiate increase in liver enzymes, specifically ALT.	Case report. ⁵	Monitor (low level of risk).
Bladderwrack <i>Fucus vesiculosus</i>			
Hyperthyroid medication eg carbimazole	May decrease effectiveness of drug due to natural iodine content. ⁶	Theoretical concern, no cases reported.	Contraindicated unless under close supervision.
Thyroid replacement therapies eg thyroxine	May add to effect of drug.	Theoretical concern linked to a case report where “kelp” caused hyperthyroidism in a person not taking thyroxine. ⁷	Monitor (low level of risk).
Bugleweed <i>Lycopus virginicus</i> , <i>Lycopus europaeus</i>			
Radioactive iodine	May interfere with administration of diagnostic procedures using radioactive isotopes. ⁸	Case report.	Contraindicated.
Thyroid hormones	Should not be administered concurrently with preparations containing thyroid hormone. ⁹	Theoretical concern based on deliberations of German Commission E.	Contraindicated.
Cat's Claw <i>Uncaria tomentosa</i>			
HIV protease inhibitors	May increase drug level.	Case report, in a patient with cirrhosis being evaluated for a liver transplant. ¹⁰	Monitor (low level of risk).
Cayenne (Chili Pepper) <i>Capsicum</i> spp. (See also Polyphenol-containing herbs)			
ACE inhibitor	May cause drug-induced cough.	Case report (topical capsaicin). Theoretical concern since capsaicin depletes substance P. ¹¹	Monitor (very low level of risk).
Theophylline	May increase absorption and drug level.	Clinical study (healthy volunteers, chili-spiced meal). Absorption and drug level lower than during fasting. ¹²	Monitor (low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Celery Seed <i>Apium graveolens</i>			
Thyroxine	May reduce serum levels of thyroxine.	Case reports. ¹³	Monitor (very low level of risk).
Chinese Skullcap <i>Scutellaria baicalensis</i>			
Losartan	May increase drug levels.	Clinical trial with healthy volunteers (water-based extract, ^a dried herb equivalent: 12 g/day). ¹⁴	Monitor (low level of risk at typical doses).
Rosuvastatin	May decrease drug levels.	Clinical study with healthy volunteers using 150 mg/day of isolated constituent (baicalin). ¹⁵	Monitor (low level of risk). ⁸
Coleus <i>Coleus forskohlii</i>			
Antiplatelet and anticoagulant drugs	May alter response to drug.	Theoretical concern initially based on <i>in vitro</i> antiplatelet activity of active constituent forskolin, and <i>in vivo</i> antiplatelet activity in an animal model (oral doses: standardized Coleus extract and forskolin). ¹⁶ More recent <i>in vivo</i> animal research: standardized Coleus extract reduced the anticoagulant activity of warfarin. ¹⁷	Monitor (low level of risk).
Hypotensive medication	May potentiate effects of drug.	Theoretical concern based on ability of high doses of forskolin and standardized Coleus extract to lower blood pressure in normotensive and hypertensive animals. ^{18,19} Clinical data from weight management trials: no effect on blood pressure in three trials, trend toward lower blood pressure in one small study. ^{20,21} No experimental or clinical studies conducted with hypotensive medication.	Monitor (low level of risk).
Prescribed medication	May potentiate effects of drug.	Theoretical concern based on ability of forskolin to activate increased intracellular cyclic AMP <i>in vitro</i> . ²²	Monitor (low level of risk).
Cranberry <i>Vaccinium macrocarpon</i>			
Midazolam	May increase drug levels.	Clinical trials with healthy volunteers: effect on drug levels conflicting – increased (double-strength juice ^c , 240 mL tds; defined as a weak interaction ^d) ²³ and no effect (cranberry juice, ^e 200 mL tds). ²⁴	Monitor (low level of risk).
Simvastatin	May increase side effects of drug.	Case report (355–473 mL/day cranberry juice drink (7% juice), rated as ‘possible’ interaction). ²⁵	Monitor (low level of risk).
Warfarin	May alter INR (most frequently increase).	Case reports (where reported the dosage was often high: up to 2000 mL/day, juice strength undefined; 1.5–2 quarts (1420–1893 mL)/day of cranberry juice cocktail; 113 g/day, cranberry sauce). ^{26–34} Clinical trials: no significant effect found in atrial fibrillation patients (250 mL/day cranberry juice cocktail), ³⁵ in patients on warfarin for a variety of indications (8 oz (236 mL)/day cranberry juice cocktail), ³⁶ but increase observed in healthy volunteers (juice concentrate equivalent to 57 g of dry fruit/day). ³⁷ No alteration of prothrombin time in patients on stable warfarin therapy (480 mL/day cranberry juice) ³⁸ or of thromboplastin time in healthy volunteers (600 mL/day cranberry juice ⁵). ²⁴ <i>See also note C.</i>	Monitor (low level of risk at typical doses).
Dong Quai <i>Angelica sinensis, Angelica polymorpha</i>			
Warfarin	May potentiate effect of drug.	Case reports: increased INR and PT; ³⁹ increased INR and widespread bruising. ⁴⁰	Monitor (low level of risk).
Echinacea <i>Echinacea angustifolia, Echinacea purpurea</i>			
Antiretroviral drugs	HIV non-nucleoside transcriptase inhibitors eg etravirine: May alter drug levels.	Clinical trial (<i>E. purpurea</i> root; HIV-infected patients): no effect overall, but large interindividual variability occurred (from near 25% decreases to up to 50% increases in drug concentrations). All maintained an undetectable viral load. ⁴¹	Monitor (low level of risk).
	HIV protease inhibitors eg darunavir: May decrease drug levels.	Clinical trial (<i>E. purpurea</i> root; HIV-infected patients): no effect overall, but some patients showed a decrease by as much as 40%. All maintained an undetectable viral load. (Patients were also taking a low dose of ritonavir). ⁴²	Monitor (low level of risk).
Immunosuppressant medication	May decrease effectiveness of drug. ^{43,44}	Theoretical concern based on immune-enhancing activity of Echinacea. No cases reported.	Contraindicated.
Midazolam	Decreases drug levels when drug administered intravenously. ⁷	Clinical study (<i>E. purpurea</i> root, 1.6 g/day). ⁴⁵	Monitor (medium level of risk) when drug administered intravenously.
Eleuthero (Siberian Ginseng) <i>Eleutherococcus senticosus</i>			
Digoxin	May increase plasma drug levels.	Case report: apparent increase in plasma level, but herb probably interfered with digoxin assay ⁶ (patient had unchanged ECG despite apparent digoxin concentration of 5.2 nmol/L). ⁴⁶ In a later clinical trial no effect observed on plasma concentration. ⁴⁷	Monitor (very low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Evening Primrose Oil <i>Oenothera biennis</i>			
Phenothiazines	May decrease effectiveness of drug.	Reports of worsening epilepsy in schizophrenics. No causal association demonstrated and no effect observed in later trials. ⁴⁸	Monitor (very low level of risk).
Garlic <i>Allium sativum</i> (See also Hypoglycemic herbs)			
Antiplatelet and anticoagulant drugs	Aspirin: May increase bleeding time. Clopidogrel: May potentiate effect of drug. Warfarin: May potentiate effect of drug. Large doses could increase bleeding tendency.	Concern may be overstated, as antiplatelet/anticoagulant drugs are often coadministered eg aspirin and warfarin. Herb Alone Case reports of increased bleeding tendency with high garlic intake. In three of the four cases the bleeding occurred after surgery. ⁴⁹⁻⁵² Anecdotal: garlic taken shortly before testing interferes with platelet aggregation in control subjects. ⁵³ <i>Single-dose studies, and studies demonstrating a beneficial effect on disordered function, including for example, in atherosclerosis, are excluded.</i> Clinical studies (3 g/day or less of fresh garlic): inhibited platelet aggregation in three trials ¹ (about 2.4-2.7 g/day, patients and healthy volunteers), ⁵⁴⁻⁵⁶ but no effect on platelet aggregation in one trial [†] (about 1.8 g/day, patients), ⁵⁷ decreased serum thromboxane in one trial (3 g/day, healthy volunteers) ⁵⁸ . † See note H. Clinical studies (4.2-5 g/day of fresh garlic, patients and healthy volunteers): no effect on platelet aggregation, fibrinogen level, prothrombin time, whole blood coagulation time. ⁵⁹⁻⁶¹ Clinical studies (8-10 g/day of fresh garlic, healthy volunteers): inhibited platelet aggregation and increased clotting time. ^{62,63} Herb and Drug Aspirin: No published studies. Clopidogrel: Garlic tablet ("odorless", dose undefined) added to improve drug therapy, reduced platelet hyperactivity in two patients. ⁵³ Warfarin: Two cases of increased INR and clotting times, very few details (garlic pearls, garlic tablets: dosage undefined). ⁶⁴ Clinical trial: no effect in healthy volunteers (enteric-coated tablets equivalent to 4 g/day of fresh garlic). ³⁷	Monitor at doses equivalent to ≥ 3 g/day fresh garlic (low level of risk). Stop taking at least one week before surgery.
HIV protease inhibitors	Decreases drug level.	Saquinavir: Two clinical studies (garlic extract, standardized for allicin content) with healthy volunteers ^{65,66} – large variability (in one study, ⁶⁶ decrease (15%) was not significant). Ritonavir-boosted atazanavir: Case report (6 stir-fried garlic cloves three times per week). ⁶⁷	Monitor (medium level of risk).
Ginger <i>Zingiber officinale</i>			
Antacids	May decrease effectiveness of drug.	Theoretical concern since ginger increases gastric secretory activity <i>in vivo</i> (animals). ⁴³	Monitor (low level of risk).
Antiplatelet and anticoagulant drugs	Phenprocoumon: May increase effectiveness of drug.	Case report (dosage undefined): increased INR. ⁶⁸	Monitor at doses equivalent to < 4 g/day dried ginger (low level of risk).
	Warfarin: Increased risk of spontaneous bleeding.	Concern based on antiplatelet activity and potential to inhibit thromboxane synthetase. Herb Alone Clinical studies: inhibition of platelet aggregation (5 g, divided single dose, dried ginger) in healthy volunteers, ⁶⁹ and coronary artery disease patients (10 g, single dose, dried ginger), ⁷⁰ but no effect in healthy volunteers (2 g, single dose, dried ginger), ⁷¹ or coronary artery disease patients (4 g/day, dried ginger); ⁷⁰ inhibition of platelet thromboxane production in healthy volunteers (5 g/day, fresh ginger). ⁷² Herb and Drug Case report: bleeding (ginger dosage undefined). ⁷³ No pharmacokinetic or pharmacodynamic effect demonstrated in a clinical trial with healthy volunteers (3.6 g/day, dried ginger). ⁷⁴ Epidemiological study: ginger (as a complementary medicine) was significantly associated with an increased risk of self-reported bleeding in patients taking warfarin. ⁷⁵ These results should be viewed cautiously (see note J).	Monitor at doses equivalent to < 4 g/day dried ginger (very low risk). Contraindicated unless under close supervision at doses equivalent to > 4 g/day dried ginger.
Nifedipine	May produce a synergistic antiplatelet effect.	Clinical study (1 g/day, dried ginger) in healthy volunteers and hypertensive patients. ⁷⁶	Contraindicated.

Drug	Potential Interaction	Basis of Concern	Recommended Action
Ginkgo* <i>Ginkgo biloba</i>			
Anticonvulsant medication eg carbamazepine, sodium valproate	May decrease the effectiveness of drug.	Case reports, two with well-controlled epilepsy, ⁷⁷ others anecdotal and uncertain. ⁷⁸⁻⁸⁰	Monitor (medium level of risk). Increasing the intake of vitamin B6 may be advisable for patients taking anticonvulsants. ¹
Antiplatelet and anticoagulant drugs	Prolongation of bleeding and/or increased bleeding tendency.	<p>Concern based on antiplatelet activity.</p> <p>Bleeding events associated with Ginkgo alone or in combination with these and other drugs have been reported but a causal relationship was not established conclusively. Although a retrospective population-based study found risk of hemorrhage was associated with elderly patients (65 years or older) who were taking Ginkgo alone.⁸¹</p> <p>Herb Alone</p> <p>Rare case reports of bleeding.⁸²⁻⁸⁴</p> <p>Meta-analysis of randomized, placebo-controlled trials (healthy volunteers and patients): results indicate standardized Ginkgo extract does not increase the risk of bleeding.⁸⁵ Randomized, 5-year trial (elderly participants; Ginkgo 50:1 extract, 240 mg/day): no significant difference in incidence of hemorrhagic events.⁸⁶</p> <p>Herb and Drug</p> <p>Retrospective population-based study in Taiwan: the relative risk of hemorrhage associated with the use of Ginkgo extract combined with drugs (clopidogrel, cilostazol, ticlopidine, warfarin) was not significant.⁸¹ See also note M.</p> <p>Aspirin: Case reports (2, bleeding;⁸² one, extensive bruising after a fall – although possibly high Ginkgo dose (400 mg/day, undefined)).⁸⁷ Clinical studies: no additional effect on platelet function, platelet aggregation or bleeding time.⁸⁸⁻⁹⁰</p> <p>Cilostazol: Clinical studies with healthy volunteers (Ginkgo extract (undefined): single dose 120 mg) – bleeding time prolonged; no change in platelet aggregation or clotting time, and no significant correlation between prolongation of bleeding time and inhibition of platelet aggregation;⁹¹ no effect on pharmacokinetics or bleeding time, the increase in platelet aggregation was not significant (Ginkgo extract (undefined): 160 mg/day).⁹²</p> <p>Clopidogrel: Case report (bruising and bleeding). Clinical study with healthy volunteers (Ginkgo extract (undefined): single dose 120 mg) – no effect on platelet aggregation, bleeding times.⁹¹</p> <p>Ticlopidine: Case report (bleeding).⁸³ Clinical studies: no significant additional effect on bleeding time or platelet aggregation (Ginkgo 50:1 extract: single dose 80 mg; healthy volunteers),⁹⁴ and at the higher dose (120 mg/day) did not affect drug levels;⁹⁵ increased inhibitory response of platelets to testing with two agonists (ie antiplatelet effect) for drug and herb compared with drug alone, although effect was small and statistical and clinical significance is unknown (Ginkgo extract (undefined): 160 mg/day; pilot study of patients who had an acute ischemic stroke or transient ischemic attack).⁹⁶</p> <p>Warfarin: Case report (bleeding).⁸² Clinical studies (healthy volunteers and patients): no additional effect on INR, platelet aggregation, coagulation parameters or plasma drug level.^{74,97,98}</p>	Monitor (low level of risk)
Antipsychotic medication eg haloperidol, olanzapine, clozapine	May potentiate the efficiency of drug in patients with schizophrenia.	Randomized, controlled trials (Ginkgo 50:1 extract: 120-360 mg/day). ⁹⁹⁻¹⁰²	Prescribe cautiously. Reduce drug if necessary in conjunction with prescribing physician.
Antiretroviral drugs	HIV integrase inhibitors eg raltegravir: May alter drug levels	Clinical study with healthy volunteers (Ginkgo 50:1 extract: 240 mg/day) found an increase in plasma levels, due to large interindividual variability, not considered to be of clinical importance. (The drug's pharmacokinetics are known for considerable intra- and interindividual variability). ¹⁰³	Monitor (low level of risk)
	HIV non-nucleoside transcriptase inhibitors eg efavirenz: May decrease drug levels.	Case report. ¹⁰⁴	Monitor (medium level of risk).
Atorvastatin – See <i>Statin drugs</i> below			
Benzodiazepines	May alter drug level.	<p>Alprazolam: Clinical trial in healthy volunteers found no effect (Ginkgo 50:1 extract: 240 mg/day).¹⁰⁵</p> <p>Diazepam: Clinical trial in healthy volunteers found no effect (Ginkgo 50:1 extract: 240 mg/day).¹⁰⁶</p> <p>Midazolam: Clinical trials in healthy volunteers found conflicting results on drug levels: increased (defined as a weak interaction⁹; Ginkgo 50:1 extract: 360 mg/day),¹⁰⁷ decreased (Ginkgo 50:1 extract: 240 mg/day)¹⁰⁸ and no effect (Ginkgo 50:1 extract: 240 mg/day).¹⁰⁹</p>	Monitor (low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Hypoglycemic drugs	Glipizide: May cause hypoglycemia.	Observation from aborted trial: hypoglycemia occurred in volunteers with normal glucose tolerance within 60 minutes. ¹¹⁰ Ginkgo 50:1 extract was administered as a single dose of 120 mg. ¹¹¹	Monitor (low level of risk).
	Metformin: May enhance effectiveness of drug.	Clinical trial: elimination half-life was increased at doses of metformin 850 mg, three times a day. Effect not significant at doses to 500 mg, twice a day. Ginkgo 50:1 extract was administered as a single dose of 120 mg. ¹¹⁰	Monitor at doses of metformin > 1 g/day (medium level of risk). Reduce drug if necessary in conjunction with prescribing physician.
	Pioglitazone: May increase drug level.	Clinical trial with healthy volunteers (Ginkgo 50:1 extract: 120 mg/day). ¹¹²	Monitor (low level of risk).
	Tolbutamide: May decrease effectiveness of drug.	Clinical trials with healthy volunteers: nonsignificant reduction in glucose-lowering effect of drug (Ginkgo 50:1 extract: 360 mg/day); ¹⁰⁷ pharmacokinetics not altered (Ginkgo 50:1 extract: 240 and 360 mg/day). ^{107,109}	Monitor (low level of risk).
Nifedipine	May increase drug levels or side effects.	Clinical studies: mixed results found for mean plasma drug level – increase (120 mg/day) ¹¹³ and no effect (240 mg/day). ¹¹⁴ However, at the higher dose, maximal plasma drug level and heart rate was increased with adverse drug reactions for participants with highest plasma drug levels (headache, dizziness, hot flashes). ¹¹⁴	Monitor at doses < 240 mg/day (medium level of risk). Contraindicated for higher doses.
Omeprazole	May decrease drug levels.	Clinical trials with healthy volunteers found conflicting results on drug levels: decreased (Ginkgo 50:1 extract: 280 mg/day) ¹¹⁵ and no effect (Ginkgo 50:1 extract: 240 mg/day). ¹⁰⁹	Monitor (low level of risk).
Statin drugs	May decrease drug levels.	Atorvastatin: Clinical study with healthy volunteers (Ginkgo 50:1 extract: 360 mg/day). No pharmacodynamic effect was observed. ¹¹⁶ Simvastatin: Clinical study with healthy volunteers (Ginkgo 50:1 extract: 240 mg/day) – drug levels decreased, but active metabolite drug levels not affected. Pharmacodynamics (cholesterol lowering) of the drug not significantly affected, although trend towards lowering of LDL-cholesterol efficacy observed. ¹¹⁷	Monitor (low level of risk).
Talinolol	May increase drug levels.	Clinical trial with healthy volunteers. ¹¹⁸	Monitor (low level of risk).
Golden Seal[®] <i>Hydrastis canadensis</i>			
Drugs which displace the protein binding of bilirubin eg phenylbutazone	May potentiate effect of drug on displacing bilirubin.	Herb Alone Theoretical concern based on <i>in vitro</i> data (displaced bilirubin from albumin) and in animals with high dose of berberine by injection (reduced bilirubin serum protein binding). ¹¹⁹	Monitor (low level of risk).
Midazolam	May increase drug level.	Clinical trial (defined as a weak interaction ⁹). ¹²⁰	Monitor (low level of risk).
Green Tea <i>Camellia sinensis</i> (See also Polyphenol-containing herbs and Tannin-containing herbs)			
Boronic acid-based protease inhibitors eg bortezomib	May decrease efficacy of drug.	Theoretical concern based on initial <i>in vitro</i> data and in vivo animal study (green tea constituent: EGCG reduced tumor cell death induced by drug). ¹²¹ However, a further <i>in vivo</i> animal study found EGCG was not antagonistic to the activity of the drug. ¹²² See <i>note P</i> .	Contraindicated at high doses (around 600 mg/day EGCG or 1 g/day green tea catechins). ⁹ More information required for doses below this level.
Folate	May decrease absorption.	Clinical study with healthy volunteers. ¹²³ Clinical significance unclear, as was a one-day study (ie not ongoing administration), with 50 mg of green tea catechins administered before, during and up to 2 hours after folate (for a total of 250 mg of catechins).	If taken simultaneously, may need to increase dose of folate. The effect may be relatively small – more information is required.
Immunosuppressives	May increase drug levels.	Case report (patient was a CYP3A4 poor metabolizer). ¹²⁴	Monitor (medium level of risk).
Sildenafil	May increase bioavailability of drug.	Clinical study with healthy volunteers (2 g, single dose, green tea powder containing 60 mg catechins). Blood pressure and electrocardiogram were unchanged. ¹²⁵	Monitor (low level of risk).
Statin drugs eg simvastatin	May increase plasma level and side effect of drug.	One case reported of muscle pain (side effect). Pharmacokinetic evaluation indicated green tea (1 cup) increased the bioavailability of simvastatin in this patient. ¹²⁶	Monitor (low level of risk).
Sunitinib	May reduce bioavailability of drug.	Case report (effect appeared dose-dependent). Considering the pharmacokinetic data (interaction in mice), the authors recommended avoiding green tea intake or leaving an interval of 4 hours between beverage and drug intake. ¹²⁷	Contraindicated , unless taken at least 4 hours apart .
Warfarin	May inhibit effect of drug: decreased INR.	Case report (brewed green tea: 0.5–1 gallon/day). ¹²⁸	Monitor (very low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Hawthorn <i>Crataegus monogyna</i> , <i>Crataegus laevigata</i> (<i>C. oxyacantha</i>) (See also Tannin-containing herbs)			
Digoxin	May increase effectiveness of drug.	Clinical studies indicate a (beneficial) synergistic effect. ^{129,130} Pharmacokinetics not affected in a clinical study (healthy volunteers). ¹³¹	Monitor (low level of risk).
Hypotensive drugs	May increase effectiveness of drug.	Controlled trials where drugs known to be taken by all or many heart disease patients: blood pressure decreased significantly (2 trials), ^{132,133} decreased nonsignificantly (1 trial) ¹³⁴ and was unchanged (1 trial). ¹³⁵ Significant decrease in blood pressure observed in diabetics taking hypotensive drugs (1 trial). ¹³⁶	Monitor (low level of risk).
Hypoglycemic herbs eg <i>Gymnema sylvestre</i> (See also Ginkgo, Korean Ginseng, Milk Thistle, St John's Wort)			
Hypoglycemic drugs including insulin	May potentiate hypoglycemic activity of drug.	In uncontrolled trials, high dose, long-term administration of <i>Gymnema</i> extract (equivalent to 10–13 g/day dried leaf) reduced insulin and hypoglycemic drug requirements in diabetics. ^{137,138} Several trials have found no effect for garlic on blood glucose in type 2 diabetes, although in a double-blind, placebo-controlled trial (using enteric-coated tablets), a reduction in the dosage of oral hypoglycemic drugs was required (these patients had fasting blood glucose above 8.0 mmol/L (144 mg/dL)). ¹³⁹	Prescribe cautiously and monitor blood sugar regularly. Warn patient about possible hypoglycemic effects. Reduce drug if necessary in conjunction with prescribing physician.
Kava <i>Piper methysticum</i>			
CNS depressants eg alcohol, barbiturates, benzodiazepines	Potential of drug effects.	Theoretical concern based on deliberations of German Commission E ⁹ and the anxiolytic activity of kava. ⁴³ Two apparent case reports (kava + benzodiazepines (alprazolam, flunitrazepam)). ^{140,141} Clinical trials with healthy volunteers: no additional side effects observed for kava (extract containing 240 mg/day of kava lactones) + benzodiazepine (bromazepam), ¹⁴² and kava (extract containing 210 mg/day of kavalactones) + alcohol. ¹⁴³ Clinical study with healthy volunteers: no effect on pharmacokinetic parameters of midazolam (extract provided 253 mg/day of kavalactones). ¹²⁰	Monitor (low level of risk).
L-dopa and other Parkinson's disease treatments	Possible dopamine antagonist effects.	Case reports. ^{144,145} Although, kava is unlikely to be responsible for central dopaminergic antagonism (experimental model) ¹⁴⁶ and kava reduced parkinsonism induced by neuroleptic drugs (observational study, psychiatric patients). ¹⁴⁷	Contraindicated unless under close supervision.
Korean Ginseng <i>Panax ginseng</i>			
Antihypertensive medications including nifedipine	General: May decrease effectiveness of drug.	Theoretical concern since hypertension is a feature of GAS. Clinical significance unclear. ⁴³ Assessment of 316 hospital patients found Korean ginseng to have a contrary effect only in a very small percentage: blood pressure increase in 5% of hypertensives; increase in 3% and decrease in 2% of normotensives; decrease in 6% of hypotensives. ¹⁴⁸ No information on concurrent medications. <i>Note for clinical trial data below:</i> Acute, single-dose trials excluded. High doses used in several trials. Herb Alone Clinical trials: no significant effects found in healthy volunteers, ^{149,150} those with metabolic syndrome, ¹⁵¹ type 2 diabetes ¹⁵² or glaucoma, ¹⁵³ although baseline blood pressure may be a factor. ¹⁵¹ Herb and Drug Clinical trials: <i>decreased</i> blood pressure in essential hypertension, ¹⁵⁴ and coronary artery disease ¹⁵⁵ but no effect in white coat hypertension ¹⁵⁴ and essential hypertension. ¹⁵⁶	Monitor (very low level of risk).
	Nifedipine: May increase drug levels.	Clinical trial. ¹¹³	Monitor (low level of risk).
Antiplatelet and anticoagulant drugs	General: May potentiate effects of drug.	Herb Alone Two epidemiological studies in Korea: long-term intake (3–5 years) prolonged plasma clotting times (APTT), ^{157,158} and decreased platelet aggregation. ¹⁵⁷ (Dosage in Korea is generally high.) Clinical trial (healthy volunteers): inhibited platelet aggregation, but no effect on coagulation (PT, APTT). ¹⁵⁹	Monitor (low level of risk).
	Warfarin: May decrease effectiveness of drug.	Herb and Drug One case reported (decreased INR) ¹⁶⁰ but clinical significance unclear. No effect demonstrated in three clinical trials (healthy volunteers and patients) for INR, prothrombin time and platelet aggregation. ^{161–163} Although the design of the trials has been criticized. <i>See note R.</i> ¹⁶⁴	Monitor (low level of risk).
Cancer chemotherapeutic drugs eg imatinib	May potentiate adverse effect possibly by altered metabolism.	Case report (hepatotoxicity; probable causality). ¹⁶⁵	Monitor (low level of risk).
CNS stimulants	May potentiate effects of drug. ⁴³	Theoretical concern since CNS stimulation is a feature of GAS. Clinical significance unclear.	Monitor (low level of risk).
HIV integrase inhibitors eg raltegravir	May potentiate adverse effect possibly by altered metabolism.	Case report (elevated liver enzymes: probable causality, dosage unknown). ¹⁶⁶	Monitor (low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Hypoglycemic drugs including insulin	May potentiate hypoglycemic activity of drug. ⁴⁴	Theoretical concern based on clinically observed hypoglycemic activity of ginseng in newly diagnosed type 2 diabetics. ¹⁶⁷ Clinical significance unclear. No effect on insulin sensitivity or beta-cell function after very high doses in newly diagnosed type 2 diabetics or those with impaired glucose tolerance. ¹⁶⁸ Korean red ginseng (2.7 g/day) reduced the requirement for insulin in about 40% of diabetics in a small uncontrolled trial. ¹⁶⁹ No adverse effects in three trials of type 2 diabetics well controlled with diet and/or oral hypoglycemic drugs. ^{152,170,171}	Monitor (low level of risk).
MAO inhibitors eg phenelzine	May cause side effects such as headache, sleeplessness, tremor.	Case reports. ¹⁷²⁻¹⁷⁴	Contraindicated.
Midazolam	May decrease drug level.	Clinical study with healthy volunteers (extract providing about 45 mg/day of ginsenosides). ¹⁷⁵	Monitor (low level of risk).
Sildenafil	Potentiation of drug possible.	Theoretical concern based on <i>in vitro</i> studies which show ginseng increases nitric oxide release from corpus cavernosum tissue. ^{176,177}	Monitor (very low level of risk).
Laxative (anthraquinone-containing) herbs eg cascara (<i>Frangula purshiana</i> , <i>Rhamnus purshianus</i>), yellow dock (<i>Rumex crispus</i>)			
Antiarrhythmic agents	May affect activity if potassium deficiency resulting from long-term laxative abuse is present.	German Commission E and ESCOP recommendation. ^{9,178}	Avoid excessive doses of laxatives. Maintain patients on a high potassium diet.
Cardiac glycosides	May potentiate activity, if potassium deficiency resulting from long-term laxative abuse is present.	German Commission E and ESCOP recommendation. ^{9,178}	Monitor (low level of risk at normal doses).
Potassium-depleting agents eg thiazide diuretics, corticosteroids, licorice root (<i>Glycyrrhiza glabra</i>)	May increase potassium depletion.	German Commission E and ESCOP recommendation. ^{9,178}	Avoid excessive doses of laxatives. Maintain patients on a high potassium diet.

Herb-Drug Interaction Chart: General Prescribing Guidelines

- Exercise great caution when prescribing herbs for patients taking drugs with a narrow therapeutic window. These drugs may become dangerously toxic or ineffective with only relatively small changes in their blood concentrations. Examples include digoxin, warfarin, antirejection (immunosuppressive) drugs, many anti-HIV drugs, theophylline, phenytoin and phenobarbital. These patients need to be monitored on a frequent, regular basis.
- Exercise great caution when prescribing herbs for patients taking drugs:
 - if heart, liver, or kidney function is impaired,
 - in elderly patients,
 - in pregnant women,
 - in those who have received an organ transplant,
 - in those with a genetic disorder that disturbs normal biochemical functions.

These patients need to be monitored on a frequent, regular basis.

- Care should be exercised with patients who exhibit long-term use of laxative herbs or potassium-losing diuretics.
- Critical drugs should be taken at different times of the day from herbs (and food) to reduce chemical or pharmacokinetic interactions. They should be separated by at least 1 hour, preferably more.
- Stop all herbs approximately 1 week before surgery. Milk thistle may help reduce the toxic after-effects of anesthetic drugs, so it can be taken up to the day before, and then again, after surgery.
- Carefully monitor the effects of drugs such as antihypertensives and antidiabetic drugs when combining with herbal remedies. The herbs may make them more or less effective. In the ideal situation the dose of the drug could be adjusted.
- Interactions may be dose related for the herb and the drug, for example, St John's wort and digoxin.

Reference and further reading: Mills S, Bone K (eds). *The Essential Guide to Herbal Safety*. Churchill Livingstone, USA, 2005.

Drug	Potential Interaction	Basis of Concern	Recommended Action
Licorice <i>Glycyrrhiza glabra</i>			
Antihypertensive medications other than diuretics	General: May decrease effectiveness of drug.	When consumed in high doses, licorice can cause pseudoaldosteronism and high blood pressure. Herb or Constituent Alone Hypertension demonstrated in case reports, usually from long-term intake and/or very high dose. ¹⁷⁹ Hypokalemic paralysis reported (184 mg/day of glycyrrhizin for 2 months), although hypertension was mild, possibly due to coexisting sodium wasting related to uropathy from prostate cancer. ¹⁸⁰ Clinical studies (up to 200 g/day of licorice): dose-dependent relationship found between licorice and increase in blood pressure, more pronounced effect in hypertensive patients than in normotensive volunteers, adverse effect greater in women, and effect shown for dose as low as 50 g/day of licorice (75 mg/day of glycyrrhetic acid = 130 mg/day of glycyrrhizin ³) taken for 2 weeks. ¹⁸¹⁻¹⁸³ Other studies show variation of effects on blood pressure (see <i>note T</i>) – renal function may be a factor. ¹⁸⁴ The increase in blood pressure after taking glycyrrhetic acid (874 mg/day of glycyrrhizin) was more pronounced in salt-sensitive than salt-resistant volunteers. ¹⁸⁵ Clinical study to establish a no-effect level for glycyrrhizin (healthy female volunteers): significant results (eg blood pressure, serum potassium and aldosterone) compared to controls found for daily dose of 4 mg/kg (220-332 mg/day) taken for 8 weeks, but no effect at lower doses of 1-2 mg/kg (55-166 mg/day) of glycyrrhizin. ¹⁸⁶ Herb and Drug Case reports (licorice tea, 3 L/day; patient still hypertensive despite treatment with drugs; ¹⁸⁷ decoction of Chinese herbs containing 5 g licorice, taken for 14 days). ¹⁸⁸	Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. ^U Place patients on a high potassium diet.
	ACE-inhibitor: May mask the development of pseudoaldosteronism.	Case report (patient consumed licorice herbal medicine (200-240 mg/day glycyrrhizin)). Drug dosage was reduced, leading to pseudoaldosteronism. ¹⁸⁹ See <i>note V</i> .	Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. ^U Place patients on a high potassium diet.
Cilostazol	May cause hypokalemia, which can potentiate the toxicity of the drug.	Case report (patient taking 150 mg/day of glycyrrhizin). Serum potassium levels were stable prior to administration of drug. ¹⁹⁰	Monitor (medium level of risk). Place patients on a high potassium diet.
Corticosteroids	Cortisol: May potentiate the action (rather than increase level of drug).	Inhibition of the enzyme 11beta-HSD2 by glycyrrhizin leads to an increased level of cortisol in the kidney. This does not happen in the liver. The plasma half-life of cortisol may be prolonged when herb and drug are coadministered, but drug concentrations remain normal, possibly because of a concomitant fall in cortisol production. ¹⁹¹ Prolonged half-life of cortisol may suggest the potential for licorice to prolong clearance (and hence, activity) of the drug. (Studies involving patients with Addison's disease or on hemodialysis are not listed here.) Herb or Constituent Alone Clinical studies with healthy volunteers ^{182,184,192-198} and patients with essential hypertension ¹⁸² (ongoing oral administration): increase in urinary excretion of cortisol, but no significant change in plasma cortisol ^{182,184,192-198} (although plasma cortisone decreased) ^{192,193,199} and diurnal variation of plasma cortisol was unaffected. ¹⁹⁵ Dosage was high: 100-200 g/day of licorice candy (containing glycyrrhizin or glycyrrhetic acid equivalent to 262-2440 mg/day of glycyrrhizin ⁵), ^{182,194,195,198} 3.5 g/day of licorice tablets (containing 266 mg/day of glycyrrhizin), ¹⁹⁶ 4.8 g/day of licorice extract (containing glycyrrhetic acid = 587 mg/day of glycyrrhizin), ¹⁹⁷ 225 mg/day glycyrrhizin, ¹⁹² glycyrrhetic acid (= 227-874 mg/day glycyrrhizin). ^{184,193} Clinical study with healthy volunteers and hypertensive patients (single dose, placebo-controlled; oral administration of glycyrrhetic acid equivalent to 874 mg/day of glycyrrhizin ⁵): increased plasma cortisol/cortisone ratio (due mostly to a decrease in plasma cortisone); salivary cortisol increased. ²⁰⁰ Clinical study with healthy volunteers (topical application of a cream containing glycyrrhetic acid): no effect on plasma cortisol. ²⁰¹ Herb or Constituent and Drug Clinical studies: increased plasma half-life of cortisol (oral administration of licorice candy (200 g/day, containing 580 mg/day glycyrrhizin) + intravenous cortisol to 7 healthy volunteers; ¹⁹⁴ oral administration of glycyrrhetic acid = 227 mg/day of glycyrrhizin ⁵ + oral cortisol to 2 volunteers). ^{202,203} See also <i>Note W</i> . <i>Ex vivo</i> study (skin samples from healthy volunteers and patients with psoriasis and eczema; glycyrrhetic acid and drug topically applied): activity of hydrocortisone potentiated by glycyrrhetic acid. ²⁰⁴	Monitor (very low level of risk at normal doses).
	Prednisolone: May potentiate the action or increase level of drug.	Herbal Constituent and Drug Two clinical studies with healthy volunteers (oral administration of glycyrrhizin or glycyrrhetic acid; ⁵ prednisolone administered intravenously): increased drug level ²⁰⁵ and increased prednisolone/prednisone ratio ^X in urine and plasma. ²⁰⁶ Dosage was high: 200 mg/day glycyrrhizin, ²⁰⁵ and 400 mg/day glycyrrhetic acid (= 700 mg/day glycyrrhizin). ²⁰⁶	Monitor (low level of risk at normal doses) when drug administered intravenously.

Drug	Potential Interaction	Basis of Concern	Recommended Action
Digoxin	May cause hypokalemia which can potentiate the toxicity of the drug.	Herb Alone Hypokalemia demonstrated in case reports and clinical studies, usually from long-term intake and/or very high dose, however effect has been demonstrated in sensitive individuals at low doses (licorice containing 100 mg/day of glycyrrhizin). Side effects would be common at 400 mg/day of glycyrrhizin. ^{179,207,208} Herb and Drug Case report (patient taking herbal laxative containing licorice (1.2 g/day) and rhubarb (<i>Rheum spp.</i> , 4.8 g/day)). In addition to digoxin, patient was also taking a potassium-depleting diuretic. ²⁰⁹	Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. ^U Place patients on a high potassium diet.
Diuretics	Spironolactone (potassium-sparing diuretic): Reduce side effects of drug.	Clinical study: in women with PCOS addition of licorice extract (containing about 463 mg/day glycyrrhizin) reduced side effects related to the diuretic activity of drug. ²¹⁰	Monitor (low level of risk at normal doses).
	Thiazide and loop (potassium-depleting) diuretics: The combined effect of licorice and the drug could result in excessive potassium loss. ⁹	Herb or Constituent Alone Hypokalemia demonstrated in case reports and clinical studies, usually from long-term intake and/or very high dose, ^{179,207,208} however effect has been demonstrated in patients for ongoing treatment with herbal medicines containing glycyrrhizin at doses of 80-240 mg/day. ²¹¹ Herb and Drug Case reports, usually from long-term intake and/or very high dose, ^{187,207,212-218} however effect has been demonstrated for ongoing treatment of glycyrrhizin as low as 80 mg/day. ²¹¹ Clinical trial (candy containing 40 mg/day of glycyrrhizin): decreased plasma potassium, with 20% of healthy volunteers hypokalemic in the first week. ²¹⁹	Contraindicated unless under close supervision at doses > 40 mg/day glycyrrhizin.
Immunosuppressives eg sirolimus	May decrease drug clearance.	Population pharmacokinetic study with 112 Chinese adult renal transplant recipients: clearance of sirolimus decreased in those patients with abnormal ALT values who were taking herbal formulations containing glycyrrhizin (route and dosage unknown). ²²⁰	Monitor (medium level of risk) in hepatically-impaired patients.
Midazolam	May decrease drug level.	Clinical study with healthy volunteers (potassium salt of glycyrrhizin, equivalent to 287 mg/day of glycyrrhizin). ²²¹	Monitor (low level of risk at normal doses).
Omeprazole	May decrease drug level.	Clinical study with healthy volunteers (potassium salt of glycyrrhizin, equivalent to 287 mg/day of glycyrrhizin). ²²²	Monitor (low level of risk at normal doses).
Potassium-depleting drugs other than thiazide and loop diuretics eg corticosteroids, stimulant laxatives	May result in excessive potassium loss.	Herb Alone Hypokalemia demonstrated in case reports and clinical studies, usually from candy intake (high dose), however effect has been demonstrated in sensitive individuals at low doses (licorice containing 100 mg/day of glycyrrhizin). Side effects would be common at 400 mg/day of glycyrrhizin. ^{179,207}	Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. ^U Place patients on a high potassium diet.
Marshmallow Root <i>Althaea officinalis</i>			
Prescribed medication	May slow or reduce absorption of drugs.	Theoretical concern based on absorbent properties of marshmallow root.	Take at least 2 hours away from medication.
Meadowsweet <i>Filipendula ulmaria</i> (See also Tannin-containing herbs)			
Warfarin	May potentiate effects of drug.	Theoretical concern based on <i>in vivo</i> animal study demonstrating anticoagulant activity (dosage unavailable). ²²³	Monitor (very low level of risk).
Milk Thistle ^K <i>Silybum marianum</i> (See also Polyphenol-containing herbs)			
Hypoglycemic drugs including insulin	May improve insulin sensitivity.	Controlled trials: improved glycemic control and reduced insulin requirements in patients with type 2 diabetes and cirrhosis (silymarin: 600 mg/day). ²²⁴ although insulin requirements unchanged in another trial (silymarin: 200 mg/day). ²²⁵ improved glycemic control in diabetics treated with hypoglycemic drugs (silymarin: 200 and 600 mg/day). ^{226,227} improved blood glucose, blood insulin and insulin resistance in PCOS patients treated with metformin (silymarin: 750 mg/day). ²²⁸ but no effect on glucose metabolism in NAFLD patients including those with insulin resistance (silymarin: 280 and 600 mg/day). ^{229,230}	Prescribe cautiously and monitor blood sugar regularly. Warn patient about possible hypoglycemic effects. Reduce drug if necessary in conjunction with prescribing physician.
Immunosuppressives eg sirolimus	May decrease drug clearance.	Population pharmacokinetic study with 112 Chinese adult renal transplant recipients: clearance of sirolimus decreased in those patients with abnormal ALT values who were taking silymarin formulations (route and dosage unknown). ²²⁰	Monitor (medium level of risk) in hepatically-impaired patients.
Losartan	May reduce efficacy of drug by inhibiting metabolism.	Clinical study (healthy volunteers; clinical significance unclear): inhibited metabolism of drug; the inhibition was greater in those of a particular CYP2C9 genotype (silymarin: 420 mg/day). ²³¹ See note Y.	Monitor (low level of risk).
Metronidazole	May decrease absorption of drug, by increasing clearance.	Clinical study with healthy volunteers (silymarin: 140 mg/day). ²³²	Monitor (medium level of risk).
Nifedipine	May delay the absorption rate of drug.	Clinical study with healthy volunteers (silymarin: 280 mg/day), but bioavailability unchanged. ²³³	Monitor (low level of risk).
Ornidazole	May increase drug levels.	Clinical study with healthy volunteers (silymarin: 140 mg/day). ²³⁴	Monitor (medium level of risk).
Talinolol	May increase drug levels.	Clinical study with healthy volunteers (silymarin: 420 mg/day). ²³⁵	Monitor (low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Phellodendron^N <i>Phellodendron amurense</i>			
Drugs that displace the protein binding of bilirubin eg phenylbutazone	May potentiate effect of drug on displacing bilirubin.	Herb Alone Theoretical concern based on <i>in vitro</i> data (displaced bilirubin from albumin) and in animals with high dose of berberine by injection (reduced bilirubin serum protein binding). ¹¹⁹	Monitor (low level of risk).
Polyphenol-containing^Z or Flavonoid-containing herbs especially cayenne (<i>Capsicum annuum</i>), chamomile (<i>Matricaria chamomilla</i> (<i>Matricaria recutita</i>)), green tea (<i>Camellia sinensis</i>), lime flowers (<i>Tilia cordata</i>), milk thistle (<i>Silybum marianum</i>), rosemary (<i>Rosmarinus officinalis</i>) (See also Tannin-containing herbs)			
Immunosuppressives eg cyclosporin	Decreases drug levels, due to impaired absorption or increased metabolism.	Three case reports, in transplant patients (2 L/day of herbal tea; 1-1.5 L/day of chamomile tea; 'large quantities' of fruit tea containing hibiscus extract, and a drink containing black tea). Confirmed by rechallenge in one case, but no signs of rejection. ²³⁶	Monitor (medium level of risk). Also advisable not to take simultaneously.
Iron	Inhibition of non-heme iron ^{AA} absorption.	Clinical study (included herb teas (German chamomile, vervain, lime flower, peppermint; all 3 g/300 mL), beverages (e.g. black tea, coffee, cocoa)): effect dependent on polyphenol content (per serving: 20-400 mg). ²³⁷ See also note BB. Timing of intake may be important. See also note CC. Epidemiological study (United States): 1 cup/week of coffee associated with 1% lower serum ferritin in the elderly. ²³⁸ Epidemiological study (China): effect for eating chili on serum ferritin in women not significant. ²³⁹ Mixed results in other studies (healthy volunteers): rosemary (32.7 mg of polyphenols) ²⁴⁰ and cayenne (high dose: 14.2 g, fresh weight, ^{DD} containing 25 mg polyphenols) ²⁴¹ caused inhibition; chamomile ²⁴² and turmeric (2.8 g, fresh weight, containing 50 mg polyphenols) ²⁴¹ did not. See also note EE. Results for green tea have been conflicting: two studies found no effect (healthy volunteers and those with anemia), ^{243,244} two studies (healthy volunteers) found an effect. ^{240,245} Drinking green tea (1:100, 1 L/day) lowered serum ferritin in women with low levels of ferritin (< 25 mcg/L) at baseline. No effect in other women or men (vegetarians and omnivores), and no effect on iron status parameters. ²⁴⁶ Two epidemiological studies (French and Japanese populations) found mixed results for serum ferritin and hemoglobin, although risk of iron depletion or anemia was not increased. ^{247,248} Clinical study (150-300 mg/day EGCG): decreased absorption in healthy women with low iron stores administered together with iron. Results significant only at higher dosage. ²⁴⁹ Concentrated extract of milk thistle reduced iron absorption in hemochromatosis patients. ²⁵⁰	In anemia and where iron supplementation is required, do not take simultaneously with meals or iron supplements.
Saw Palmetto <i>Serenoa repens</i>			
Antiplatelet and anticoagulant drugs	May potentiate effect of drug.	Herb Alone Case report (hemorrhage during surgery). ²⁵¹ Clinical trials: <i>reduced</i> intraoperative bleeding from transurethral resection of the prostate procedure with preoperative use of liposterolic extract (2 trials); blood loss not different when compared with drug treatment (1 trial). ²⁵² Herb and Drug Case reports (2): increased INR (warfarin + simvastatin, ²⁵³ aspirin + clopidogrel; ²⁵⁴ – in the first case, the interaction may have been due to the vitamin E also present in the preparation; ²⁵⁵ in the second case, six times the usual dose of extract was taken).	Monitor (very low level of risk).
Schisandra <i>Schisandra chinensis</i>			
Immunosuppressives	May increase drug levels.	Sirolimus: Observations in some liver transplanted recipients. Clinical study: markedly increased drug levels in healthy volunteers ²⁵⁵ given <i>S. sphenanthera</i> extract, providing 67.5 mg/day of deoxyschisandrin ^{FF} . Tacrolimus: Observations in some renal and liver transplanted recipients. Clinical studies: markedly increased drug levels in healthy volunteers ²⁵⁶ and transplant recipients, ^{257,258} given <i>S. sphenanthera</i> extract, providing 67.5 mg/day of deoxyschisandrin ^{FF} .	Monitor (low level of risk at normal doses).
Midazolam	May increase drug levels.	Increased drug level (defined as a moderate interaction ⁹), increase in sleeping time and increase in mild to moderate adverse effects found in healthy volunteers, given <i>S. chinensis</i> extract, providing 22.5 mg/day of deoxyschisandrin ^{FF} . ²⁵⁹	Monitor (medium level of risk at normal doses).
Prescribed medication	May accelerate clearance from the body.	Theoretical concern based on <i>in vivo</i> animal studies demonstrating enhanced phase I/II hepatic metabolism. ^{260,261}	Monitor (medium level of risk).
Talinolol	May increase drug levels.	Increased drug level and decreased clearance found in healthy volunteers, given <i>S. chinensis</i> extract, providing 33.75 mg/day of deoxyschisandrin ^{FF} . ¹¹⁸	Monitor (low level of risk at normal doses).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Slippery Elm Bark <i>Ulmus rubra</i>			
Prescribed medication	May slow or reduce absorption of drugs.	Theoretical concern based on absorbent properties of slippery elm.	Take at least 2 hours away from medication.
St John's Wort ^{5G} <i>Hypericum perforatum</i> (See also Tannin-containing herbs)			
Amitriptyline	Decreases drug levels. ²⁶²	Clinical study.	Monitor (medium level of risk).
Anticonvulsants eg carbamazepine, mephenytoin, phenobarbitone, phenytoin	May decrease drug levels via CYP induction. ²⁶³⁻²⁶⁵	Theoretical concern. An open clinical trial demonstrated no effect on carbamazepine pharmacokinetics in healthy volunteers. ²⁶⁶ Case report: increase in seizures in patient taking several antiepileptic drugs, two of which are not metabolized by cytochrome P450. ²⁶⁷ Clinical study (healthy volunteers; clinical significance unclear): increased excretion of a mephenytoin metabolite in extensive metabolizers, but not in poor metabolizers. ²⁶⁸ See note HH.	Monitor (low level of risk).
Antihistamine eg fexofenadine	Decreases drug levels.	Clinical studies. ^{269,270}	Monitor (medium level of risk).
Antiplatelet and anticoagulant drugs	Clopidogrel: May potentiate effects of drug.	Clinical studies: increased responsiveness (decreased platelet aggregation or improved residual platelet reactivity) in hyporesponsive volunteers and patients, ²⁷¹⁻²⁷⁴ possibly via the formation of the active metabolite (CYP3A4 activity was increased), thus providing a beneficial effect in these patients. This is a complex situation, with the meaning of clopidogrel resistance/hyporesponsiveness debated. ^{271,275}	In patients with known clopidogrel resistance: Monitor (medium level of risk). In other patients: Monitor (risk is unknown).
	Phenprocoumon: Decreases plasma drug levels.	Clinical study. ²⁷⁶	Contraindicated.
	Warfarin: Decreases drug levels and INR.	Case reports (decreased INR (nine cases), increased INR (three cases)). ²⁷⁷⁻²⁷⁹ Clinical study with healthy volunteers (decreased drug level and INR). ¹⁶¹	Contraindicated.
Benzodiazepines	Decreases drug levels, and is probably dependent upon the hyperforin content. ²⁸⁰	Alprazolam: Mixed results for drug levels in two clinical studies (similarly low amount of hyperforin, ~4 mg/day) – no effect (dried herb equivalent: 1.1 g/day) ²⁸¹ and decrease. ²⁸²	Monitor (medium level of risk).
		Midazolam: Clinical studies, effect not regarded as clinically relevant for low (< 1 mg/day) hyperforin extracts. ^{270,280,283,284}	Hyperforin-rich extracts: Monitor (medium level of risk). Low-hyperforin extracts: Monitor (low level of risk).
		Quazepam: Decreased drug levels, but no effect on pharmacodynamics (sedation). ²⁸⁵	Monitor (low level of risk).
Calcium channel antagonists	Decreases drug levels.	Nifedipine: Clinical studies. ^{113,286}	Contraindicated.
		Verapamil: Clinical study. ²⁸⁷	Contraindicated.
Cancer chemotherapeutic drugs eg irinotecan, imatinib	Decreases drug levels.	Clinical studies. ²⁸⁸⁻²⁹¹	Contraindicated.
Clozapine	Decreases drug levels.	Case report. ²⁹²	Contraindicated.
Digoxin	Decreases drug levels.	Clinical studies (several studies showed decrease, one study showed no effect) ^{281,293-295} but effect is dependent upon dose of herb and the hyperforin content. ²⁹⁵	Contraindicated at doses equivalent to > 1 g/day dried herb, especially for high-hyperforin extracts.
Docetaxel (intravenous)	May decrease effectiveness of drug.	Clinical study with cancer patients: ²⁹⁶ effect on pharmacokinetics probably not clinically relevant (eg plasma levels decreased by only 6%); drug-induced side effects were also reduced. See also Note JJ.	Contraindicated.
Finasteride	May decrease drug levels.	Clinical study with healthy volunteers. ²⁹⁷ Case report: PSA level elevated (due to decreased efficacy of drug?) in patient with benign prostatic hyperplasia. ²⁹⁸	Contraindicated.
HIV non-nucleoside transcriptase inhibitors eg nevirapine	Decreases drug levels.	Case report. ²⁹⁹	Contraindicated.
HIV protease inhibitors eg indinavir	Decreases drug levels.	Clinical study. ³⁰⁰	Contraindicated.

Drug	Potential Interaction	Basis of Concern	Recommended Action
Hypoglycemic drugs	Gliclazide: May reduce efficacy of drug by increased clearance.	Clinical study with healthy volunteers, but glucose and insulin response to glucose loading were unchanged. ³⁰¹	Monitor (low level of risk).
	Repaglinide: May alter metabolism of drug.	Clinical study with healthy volunteers: no effect, and glucose and insulin response to glucose loading were unchanged. ³⁰²	Monitor (very low level of risk).
	Tolbutamide: May affect blood glucose.	Two clinical studies (healthy volunteers): no effect on pharmacokinetics, ^{281,283} but there was an increased incidence of hypoglycemia in the trial using hyperforin-rich extract (33 mg/day). ²⁸³	Monitor (low level of risk).
Immunosuppressives	Decreases drug levels.	Cyclosporin: Case reports, ³⁰³⁻³¹¹ case series, ³¹²⁻³¹³ clinical studies. ^{270,314} Interaction is dependent upon the hyperforin content. ^{306,316} Tacrolimus: Case report and clinical studies. ³¹⁵⁻³¹⁷	Contraindicated especially for high-hyperforin extracts.
Ivabradine	May decrease drug levels.	Clinical trial with healthy volunteers. No pharmacodynamic effect was observed. ³¹⁸	Monitor (medium level of risk).
S-Ketamine (oral)	May decrease drug levels.	Clinical study with healthy volunteers. No pharmacodynamic effect was observed (eg analgesic effect not altered). ³¹⁹	Monitor (medium level of risk).
Methadone	Decreases drug levels, possibly inducing withdrawal symptoms.	Case reports. ³²⁰	Contraindicated.
Methylphenidate	May decrease efficacy.	Case report, ³²¹ but clinical significance unclear.	Monitor (low level of risk).
Morphine (oral)	May potentiate effects of drug.	Clinical study (healthy volunteers): ³²² pain scores were decreased when morphine co-administered with standardized extract at a dose of herb below those used to obtain an antidepressant or analgesic effect. The effect was dependent hypericin content, but not hyperforin. The authors suggest the herb may be able to decrease the dose of morphine while obtaining the same analgesic effect.	Monitor (medium level of risk).
Omeprazole	May decrease drug levels.	Clinical trial. ³²³	Monitor (low level of risk).
Oral contraceptives	May increase metabolism and reduce effectiveness of drug.	Breakthrough bleeding reported which was attributed to increased metabolism of drug. ^{277,303} Clinical significance unclear. Cases of unwanted pregnancies have been reported. ³²⁴⁻³²⁶ Contradictory results for effect on bioavailability, hormone levels and ovulation demonstrated in three clinical studies, although some breakthrough bleeding occurred. ³²⁷⁻³²⁹ In one clinical trial an extract low in hyperforin did not affect plasma contraceptive drug levels or cause breakthrough bleeding. ³³⁰ Clinical trial: clearance of levonorgestrel at emergency contraceptive doses increased (not statistically significant). ³³¹ Clinical study: antiandrogenic effect of contraceptive not affected. ³³²	Hyperforin-rich extracts: Monitor (medium level of risk). Low-hyperforin extracts: Monitor (very low level of risk).
Oxycodone	Decreases drug levels.	Clinical trial with healthy volunteers. ³³³	Monitor (medium level of risk).
SSRIs eg paroxetine, trazodone, sertraline and other serotonergic agents eg nefazodone, venlafaxine	Potential effects possible in regard to serotonin levels.	Case reports: clinical significance unclear. ³³⁴⁻³³⁹	Monitor (very low level of risk).
Statin drugs	May decrease effect and/or drug levels.	Atorvastatin: Clinical study, serum LDL-cholesterol increased by 0.32 mmol/L (12.3 mg/dL) which corresponds to a decrease in effect of drug in patients by about 30%. Serum total cholesterol was also increased. ³⁴⁰ Pravastatin: Clinical study, no effect on plasma level in healthy volunteers. ³⁴¹ Rosuvastatin: Case report. ³⁴² Simvastatin: Two clinical studies, decrease in drug levels in healthy volunteers, ³⁴¹ and small increases in serum total cholesterol and LDL-cholesterol in patients. ³⁴³	Monitor blood cholesterol regularly (medium level of risk).
Talinolol	May decrease drug levels.	Clinical study with healthy volunteers. ³⁴⁴	Monitor (medium level of risk).
Theophylline	May decrease drug levels.	Case report. ³⁴⁵ No effect observed in clinical study. ³⁴⁶	Monitor (low level of risk).
Voriconazole	Decreases drug levels.	Clinical study. ³⁴⁷	Monitor (medium level of risk).
Zolpidem	May decrease drug levels (but with wide interindividual variability). ^{xx}	Clinical study (healthy volunteers). ³⁴⁸	Monitor (low level of risk).

Drug	Potential Interaction	Basis of Concern	Recommended Action
Tannin-containing or OPC-containing herbs eg grape seed extract (<i>Vitis vinifera</i>), green tea (<i>Camellia sinensis</i>), hawthorn (<i>Crataegus</i> spp.), meadowsweet (<i>Filipendula ulmaria</i>), pine bark (<i>Pinus massoniana</i>), raspberry leaf (<i>Rubus idaeus</i>), sage (<i>Salvia fruticosa</i>), St John's wort (<i>Hypericum perforatum</i>), uva ursi (<i>Arctostaphylos uva-ursi</i>), willow bark (<i>Salix</i> spp.) (See also Polyphenol-containing herbs)			
Minerals especially iron	Iron: May reduce absorption of non-heme iron ^{6A} from food.	Clinical studies in healthy volunteers, administration during or immediately following the meal ^{237,349-356} (black tea, typical strength: 0.8–3.3 g/100 mL; ^{237,349-355} sorghum ⁴⁴ (0.15% tannins) ³⁵⁴), and in women with iron deficiency anemia ³⁵⁷ (black tea: 1–2 x 150 mL of 1:100 infusion containing 78 mg of tannins per 150 mL). ³⁵⁷ Iron absorption reduced to a greater extent in those with iron deficiency anemia (IDA). ³⁵⁷ However, the results from single test meals may exaggerate the effect of iron inhibitors and enhancers. ³⁵⁸ Effects were not significant in a 14-day study. ²⁴⁵ Cases of IDA resistant to treatment: heavy black tea drinkers (2 cases, 1.5–2 L/day). ^{359,360} Epidemiological studies (12, to 2002) found mixed results, but some evidence of an association between drinking black tea and poor iron status. ³⁵⁸ Clinical study in patients with hemochromatosis (black tea: 250 mL with meal). ³⁶¹	Take at least 2 hours away from food or medication.
	Zinc: May reduce absorption from food.	Clinical studies with healthy volunteers: results conflicting for effect on zinc (undefined tea, ³⁶² black tea ²⁴⁵ consumed at or immediately after food).	Take at least 2 hours away from food or medication.
Turmeric^N <i>Curcuma longa</i>			
Talinolol	May decrease drug levels.	Clinical study with healthy volunteers (300 mg/day of curcuminoids). ³⁶³	Monitor at high doses (\geq 300 mg/day curcumin, low level of risk).
Valerian <i>Valeriana officinalis</i>			
CNS depressants or alcohol	May potentiate effects of drug.	Theoretical concern expressed by US Pharmacopeial Convention. ³⁶⁴ However a clinical study found no potentiation with alcohol. ³⁶⁵ Case report of adverse effect with benzodiazepine drug (lorazepam) ³⁶⁶ – herb dosage undefined but likely high (tablet contained valerian and passionflower (<i>Passiflora incarnata</i>)). Alprazolam: Clinical study in healthy volunteers found no effect on drug levels (extract provided 11 mg/day total valerenic acids). ³⁶⁷	Monitor (very low level of risk).
Willow Bark <i>Salix alba</i> , <i>Salix daphnoides</i> , <i>Salix purpurea</i> , <i>Salix fragilis</i> (See also Tannin-containing herbs)			
Warfarin	May potentiate effects of drug.	Herb Alone Clinical study observed very mild but statistically significant antiplatelet activity (extract containing 240 mg/day of salicin). ³⁶⁸	Monitor (low level of risk).
CODE FOR RECOMMENDED ACTION			
Contraindicated: Do not prescribe the indicated herb.			
Monitor: Can prescribe the indicated herb but maintain close contact and review the patient's status on a regular basis. Note that where the risk is assessed as medium, self-prescription of the herb in conjunction with the drug is not advisable.			
ABBREVIATIONS			
ACE: angiotensin-converting enzyme; ALT: alanine transaminase, also known as glutamic pyruvic transaminase (GPT); AMP: adenosine monophosphate; APTT: activated partial thromboplastin time; AUC: area under the plasma/serum concentration-time curve (measures extent of absorption); CNS: central nervous system; CYP: cytochrome P450; ECG: electrocardiogram/graph; EGCG: epigallocatechin gallate; GAS: ginseng abuse syndrome; HIV: human immunodeficiency virus; 11beta-HSD2: 11beta-hydroxysteroid dehydrogenase type 2; IDA: iron deficiency anemia; INR: international normalized ratio; LDL: low density lipoprotein; NAFLD: nonalcoholic fatty liver disease; OPC: oligomeric procyanidin; PCOS: polycystic ovary syndrome; PSA: prostate specific antigen; PT: prothrombin time; SSRI: selective serotonin reuptake inhibitors; tds: three times per day; >: greater than; \geq: greater than or equal to; <: less than.			

Health care professionals please note: when a patient presents using any of the drugs listed below and there is a potential interaction with the herb you intend to dispense, it is important that you or your patient discuss the potential interaction with their prescribing physician before you dispense the herb to the patient.

NOTES

- * This chart contains information the authors believe to be reliable or which has received considerable attention as potential issues. However, many theoretical concerns expressed by other authors have not been included. Due to the focus on safety, positive interactions between herbs and drugs, and the effect of drugs on the bioavailability of herbs are generally not included.
- A. Research paper describes administration of *Scutellaria radix*. Trial authors confirm this was root of Chinese skullcap (*Scutellaria baicalensis*).³⁶⁹
- B. Analysis of Chinese skullcap root samples from Japan found the baicalin content varied from 3.5 to 12%. For a dose of 150 mg/day of baicalin, 1.2–4.3 g/day of dried root would be required.³⁷⁰
- C. Single-strength (freshly squeezed, 100%) cranberry juice is highly acidic and astringent, making it unpalatable. For this reason, cranberry juice is usually diluted and sweetened (often known as cranberry juice drink). Cranberry juice cocktail usually contains 25% cranberry juice, although can be up to 35%. Cranberry juice drinks contain about 10% cranberry juice. Cranberry sauce is about half the strength of cranberry juice cocktail, about the same strength as juice drinks. Cranberry juice can be concentrated to a dry powder (unsweetened and usually up to 25:1) and used in tablets and capsules. Juices can be prepared by diluting juice concentrates yielding a concentrated juice (eg double-strength juice, at twice the strength of single-strength, squeezed juice). It is likely that unless defined, cranberry juice referred to in case reports and clinical studies is juice drink containing around 10% cranberry juice.
- D. Refer to Assessment of Risk & Recommended Action (available on www.mediherb.com) for definition of the extent of this interaction.
- E. The cranberry 'juice' administered was similar in concentration to a reference cranberry 'juice' containing about 25% cranberry juice,³⁷¹ but with a higher concentration of anthocyanins, and lower in catechins and organic acids. See also note C.
- F. No effect overall when midazolam was administered orally: oral clearance and area under the drug concentration-time curve were unchanged.
- G. Eleutherosides (from Eleuthero) and ginsenosides (from Korean ginseng) have some structural similarity with digoxin. Because of this similarity interference with serum digoxin measurements is possible, as confirmed when mice fed these herbs demonstrated digoxin activity in their serum. More specific assays are able to negate the interference.³⁷²
- H. These four trials used tablets containing a concentrated, standardized extract. A dosage of 900 mg/day of dry extract was equivalent to about 2.7 g/day of fresh garlic,³⁷³ and was said to provide 12 mg/day of alliin,^{54,62} although there is some doubt as to the amount of allicin released from this brand of tablet from around 1995 to 2000.³⁷⁴
- J. There may have been variation in patients' interpretations (of bleeding) and the significant association between ginger use and bleeding was based on 7 self-reported events in 25 users.³⁷⁵
- K. Information is provided for specialized and/or concentrated extract, rather than galenical form of herb.
- L. Ginkgotoxin (4'-O-methylpyridoxine) is present in substantial amounts in Ginkgo seed, and convulsions arising from ingestion of Ginkgo seed have been documented in Japan (infants are particularly vulnerable). Ginkgotoxin is known to inhibit vitamin B6 phosphorylation, which may lead to increased neuronal excitability.³⁷⁶ Poisoning by ginkgotoxin can be counteracted by vitamin B6,³⁷⁶ in cases of poisoning it is administered by intravenous injection.^{377,378} Ginkgotoxin is present in very small amounts in standardized Ginkgo leaf extracts,³⁷⁹ but is below the detection limits in human plasma after oral doses (240 mg of 50:1 extract, equivalent to 12 g of dried leaf).³⁸⁰ According to the manufacturer, despite the extensive use of this special extract (more than 150 million daily doses per year for more than two decades) no cases of epileptic seizure have been attributed to this extract.³⁸⁰ (Ginkgo preparations associated with the above case reports were undefined.) Strictly speaking this is a potential adverse effect (rather than a herb-drug interaction) as there is no pharmacokinetic data indicating an interaction for coadministration of Ginkgo and anticonvulsants in humans. An interaction is suggested though, because Ginkgo has been found to induce CYP2C19 activity (see entry for omeprazole), an enzyme involved in the metabolism of some anticonvulsants.^a
- M. Analysis of over 320 000 patients in a German adverse drug reaction reporting system (1999–2002) found no increase in prevalence of bleeding during Ginkgo intake compared to periods without Ginkgo in those taking anticoagulant or antiplatelet medication.³⁸¹ In a trial involving 3069 healthy volunteers treated for an average of 6.1 years, there were no statistically significant differences between placebo and Ginkgo in the rate of major bleeding or the incidence of bleeding in individuals taking aspirin. (Compliance during the trial was however low (at the end of the trial, about 60% were taking Ginkgo/placebo).)³⁸² In Korea, Ginkgo extract is administered with ticlopidine for the prevention of ischemic stroke or acute coronary syndrome.³⁸³
- N. Information is provided for herbs containing standard levels of active constituents. See elsewhere for information on extracts containing very high levels of active constituents such as berberine and curcumin.
- P. The *in vitro* reduction by EGCG was overcome when the concentration of the drug was increased (to a level expected clinically ie in plasma from the standard drug dose).³⁸⁴ A further *in vivo* study found no reduction in the activity of the drug (when EGCG administered by injection to achieve plasma levels of 11–16 microM).¹²²
- Q. The *in vitro* study found a pronounced reduction in the cytotoxic effect of the drug for a concentration of 2.5–5 microM of EGCG, and when applied as green tea polyphenols a very substantial effect occurred at a EGCG concentration of 1 microM (the other polyphenols may contribute to the activity).¹²¹ A pharmacokinetic study with healthy volunteers found a EGCG plasma concentration of 0.7 microM after a dose of 580 mg of EGCG, and a EGCG plasma concentration of 0.5 microM after a dose of 1 g of green tea polyphenols.³⁸⁵
- R. A better design would have volunteers take warfarin alone for a period long enough to allow the drug to reach its maximum effect (about 3–5 days) before adding the herb.
- S. Glycyrrhetic acid, is the aglycone of glycyrrhizin. Glycyrrhizin, is the glycoside and contains the aglycone (glycyrrhetic acid) and a sugar unit.

- T. No effect on blood pressure in healthy volunteers in two studies (130 mg/day of glycyrrhetic acid = 227 mg/day of glycyrrhizin, for 14 days;¹⁸⁴ licorice tablets (266 mg/day of glycyrrhizin) for 56 days);¹⁹⁶ including where plasma renin levels were high (3.1 ng/mL/h),¹⁹⁶ but in another study, blood pressure increased in healthy volunteers taking 546 mg/day of glycyrrhizin for 4 weeks, only for those with plasma renin activity greater than 1.5 ng/mL/h.³⁸⁶
- U. This is a guide, based on a recommendation from the German Commission E for long-term consumption of licorice as a flavoring. Glycyrrhizin is also known as glycyrrhizic acid and glycyrrhizic acid.
- V. ACE-inhibitors cause mild natriuresis (an increase in sodium excretion in the urine) and occasionally hyperkalemia. The mechanism of the interaction is not known, although it may involve opposing effects on 11 β -hydroxysteroid dehydrogenase type 2 (glycyrrhizin inhibiting, ACE-inhibitor promoting), thus affecting mineralocorticoid receptor activity. Reduction of drug dosage revealed the existing hypokalemia caused by this dosage of glycyrrhizin.
- W. Maximum plasma cortisol (exogenous) was not increased in one volunteer;²⁰³ in the other, plasma (exogenous) cortisone/cortisol ratio decreased,²⁰² suggesting increased (exogenous) cortisol while (endogenous) cortisol decreased (although statistical and clinical significance is unknown, and may have been within the normal range). In these studies isotope-labelled cortisol was administered, which allowed exogenous and endogenous cortisol to be measured.
- X. A higher prednisolone/prednisone ratio indicates decreased conversion of prednisolone (active) to prednisone (inactive).
- Y. Several variants of CYP2C9 have been identified in humans: the most important mutations are CYP2C9*2 and CYP2C9*3. The CYP2C9*3 variant shows decreased metabolic activity for many drugs metabolized by CYP2C9. CYP2C9 is the main enzyme responsible for transforming losartan to its active metabolite.
- Z. The word tannin has a long established and extensive usage although it is considered in more recent years to lack precision. Polyphenol is the preferred term when considering the properties at a molecular level. Plant polyphenols are broadly divisible into proanthocyanidins (condensed tannins) and polymers of esters based on gallic and/or hexahydroxydiphenic acid and their derivatives (hydrolyzable tannins).³⁸⁷ The terms 'tannin' and 'polyphenol' are sometimes used interchangeably. For example, the results of a clinical study are described: "polyphenols present in tea and coffee inhibited iron absorption in a dose-dependent manner". The 'polyphenol' content was measured using a spectrophotometric method for the determination of "tannins and other polyphenolics".³⁵⁶ Depending on the analytical method used, it is possible that the polyphenol content may actually be the content of tannins or tannins + polyphenols.³⁸⁸ It is recommended that both sections of this chart be considered: Polyphenol-containing or Flavonoid-containing herbs, and Tannin-containing or OPC-containing herbs.
- AA. Heme iron is derived from hemoglobin and myoglobin mainly in meat products. Non-heme iron is derived mainly from cereals, vegetables and fruits.
- BB. At an identical concentration of total polyphenols, black tea was more inhibitory than all the herb teas excluding peppermint: black tea was of equal inhibition to peppermint tea.²³⁷ The type of polyphenols present, as well as the concentration, may affect iron absorption.
- CC. Another clinical study also found a dose-dependent effect, and the reduced absorption was most marked when coffee was taken with the meal or one hour later. No decrease in iron absorption occurred when coffee was consumed one hour before the meal.³⁵⁵
- DD. Administered in freeze-dried form (4.2 g), which would be expected to have a lower inhibitory effect than with the use of fresh chili, as freeze drying probably decreased the ascorbic acid content (ascorbic acid enhances iron absorption).²⁴¹
- EE. The different results for cayenne and turmeric under the same experimental conditions, suggest it is not only the quantity of polyphenol present that determines the inhibition, but also for example, the structure of the polyphenol (and hence mechanism of iron binding).²⁴¹
- FF. Fructus Schisandra is defined as the fruit of *Schisandra chinensis* or *Schisandra sphenanthera* in traditional Chinese medicine. The major constituents are dibenzocyclooctene lignans. Several factors including harvest season, origin of herb and extraction solvent affect the levels of the individual lignans. Aqueous or ethanolic extracts of *S. chinensis* are not likely to contain more than 2.5 mg/g of deoxyschisandrin.^{389,390} A maximum dose of *S. chinensis* extract equivalent to 4 g/day, would provide 10 mg/day of deoxyschisandrin.
- GG. As noted for several drugs, the hyperforin content of the St John's wort preparation, as well as the dosage of herb, affects the extent of the interaction. All types of preparations can contain hyperforin, including dry extracts used in tablets and capsules. Hyperforin is however, unstable – particularly when in solution.³⁹¹ Tinctures and liquid extracts made using a standard ethanol content (45%) contain negligible amounts of hyperforin. Liquid extracts using a higher ethanol content (such as 60%) will contain a higher initial amount of hyperforin than standard liquid extracts. Over time the hyperforin content is substantially reduced and after a few months tinctures and liquid extracts contain no hyperforin.³⁹²
- HH. Genetic polymorphisms are important in determining differences in the response to drugs, and may influence interactions. There are many genetic variants of the CYP genes, including the CYP2C19 gene. Phenotypes of CYP2C19 have been classified functionally as extensive metabolizers and poor metabolizers, the latter having a deficiency of CYP2C19 activity.^{222,393}
- JJ. Two of the 10 patients with the highest hyperforin levels prior to drug administration showed the greatest decrease in the AUC_∞ of docetaxel, for the other patients, no apparent correlation between hyperforin levels and the docetaxel AUC_∞ was observed.
- KK. Of the 14 volunteers, in three, a small increase in AUC was observed after administration of St John's wort.
- LL. Sorghum also contains phytate. Both phytate and polyphenol inhibit nutrients such as iron.^{394,395}

REFERENCES

Braun L. *Herb Drug Interaction Guide for Pharmacists*. FH Faulding, August 2000; Fugh-Berman A. *Lancet* 2000; **355**(9198): 134-138

- 1 Pulliero G, Montin S, Bettini V et al. *Fitoterapia* 1989; **60**(1): 69-75
- 2 Duterte M, Waugh S, Thanawala R. *Am J Gastroenterol* 2007; **102**(Suppl 2): S350
- 3 Neumann L. *Klin Monb Augenheilkd* 1973; **163**(1): 96-103
- 4 Aktas C, Senkal V, Sarikaya S et al. *Turk J Geriatr* 2011; **14**(1): 79-81
- 5 Patel NM, Derkits RM. *J Pharm Pract* 2007; **20**(4): 341-346
- 6 de Smet PAGM, Keller K, Hansel R et al (eds). *Adverse Effects of Herbal Drugs*, Volume 3. Springer-Verlag, Berlin, 1997.
- 7 Miller LG. *Arch Intern Med* 1998; **158**(20): 2200-2211
- 8 de Smet PAGM, Keller K, Hansel R et al (eds). *Adverse Effects of Herbal Drugs*, Volume 2. Springer-Verlag, Berlin, 1993.
- 9 Blumenthal M et al (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, 1998.
- 10 Lopez Galera RM, Ribera Pascuet E, Esteban Mur JJ et al. *Eur J Clin Pharmacol* 2008; **64**(12): 1235-1236
- 11 Hakas JF. *Ann Allergy* 1990; **65**(4): 322-323
- 12 Bouraoui A, Toum A, Bouchoucha S et al. *Therapie* 1986; **41**(6): 467-471
- 13 Moses G. *Australian Prescriber* 2001; **24**(1): 6
- 14 Yi SJ, Cho JY, Lim KS et al. *Basic Clin Pharmacol Toxicol* 2009; **105**(4): 249-256
- 15 Fan L, Zhang W, Guo D et al. *Clin Pharmacol Ther* 2008; **83**(3): 471-476
- 16 de Souza NJ. *J Ethnopharmacol* 1993; **38**(2-3): 177-180
- 17 Yokotani K, Chiba T, Sato Y et al. *J Pharm Pharmacol* 2012; **64**(12): 1793-1801
- 18 de Souza NJ, Dohadwalla AN, Reden J. *Med Res Rev* 1983; **3**(2): 201-219
- 19 Dubey MP, Srimal RC, Nityanand S et al. *J Ethnopharmacol* 1981; **3**(1): 1-13
- 20 Sabinsa Corporation. *ForsLean® Product Information*. Available from www.forslean.com. Accessed November 2004.
- 21 Henderson S, Magu B, Rasmussen C et al. *J Int Soc Sports Nutr* 2005; **2**(2): 54-62
- 22 Seamon KB, Daly JW. *J Cyclic Nucleotide Res* 1981; **7**(4): 201-224
- 23 Ngo N, Yan Z, Graf TN et al. *Drug Metab Dispos* 2009; **37**(3): 514-522
- 24 Lijla JJ, Backman JT, Neuvonen PJ. *Clin Pharmacol Ther* 2007; **81**(6): 833-839
- 25 Goldenberg G, Khan R, Bharathan T. *Clin Geriatrics* 2012; **20**(8): 38-42
- 26 Medicines and Healthcare Products Regulatory Agency, Committee on Safety of Medicines. *Current Problems in Pharmacovigilance*, Vol 30, October 2004, p 10.
- 27 Rindone JP, Murphy TW. *Am J Ther* 2006; **13**(3): 283-284
- 28 Sylvan L, Justice NP. *Am Fam Physician* 2005; **72**(6): 1000
- 29 Paeng CH, Sprague M, Jackevicius CA. *Clin Ther* 2007; **29**(8): 1730-1735
- 30 Welch JM, Forster K. *J Pharm Technol* 2007; **23**(2): 104-107
- 31 Mergenhagen KA, Sherman O. *Am J Health Syst Pharm* 2008; **65**(22): 2113-2116
- 32 Griffiths AP, Beddall A, Pegler S. *J R Soc Promot Health* 2008; **128**(6): 324-326
- 33 Hamann GL, Campbell JD, George CM. *Ann Pharmacother* 2011; **45**(3): e17
- 34 Haber SL, Cauthon KA, Raney EC. *Consult Pharm* 2012; **27**(1): 58-65
- 35 Li Z, Seeram NP, Carpenter CL et al. *J Am Diet Assoc* 2006; **106**(12): 2057-2061
- 36 Ansell J, McDonough M, Zhao Y et al. *J Clin Pharmacol* 2009; **49**(7): 824-830
- 37 Mohammed Abdul MI, Jiang X, Williams KM et al. *Br J Pharmacol* 2008; **154**(8): 1691-1700
- 38 Mellen CK, Ford M, Rindone JP. *Br J Clin Pharmacol* 2010; **70**(1): 139-142
- 39 Page RL, Lawrence JD. *Pharmacotherapy* 1999; **19**(7): 870-876
- 40 Ellis GR, Stephens MR. *BMJ* 1999; **319**(7210): 650
- 41 Moltó J, Valle M, Miranda C et al. *Antimicrob Agents Chemother* 2012; **56**(10): 5328-5331
- 42 Moltó J, Valle M, Miranda C et al. *Antimicrob Agents Chemother* 2011; **55**(1): 326-330
- 43 Mills S, Bone K. *Principles and Practice of Phytotherapy: Modern Herbal Medicine*. Churchill Livingstone, Edinburgh, 2000.
- 44 Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines – A Guide for Health-Care Professionals*. Pharmaceutical Press, London, 1996.
- 45 Gorski JC, Huang SM, Pinto A et al. *Clin Pharmacol Ther* 2004; **75**(1): 89-100
- 46 McRae S. *Can Med Assoc J* 1996; **155**(3): 293-295
- 47 Cicero AF, Derosa G, Brillante R et al. *Arch Gerontol Geriatr Suppl* 2004; (9): 69-73
- 48 Mills S, Bone K. *The Essential Guide to Herbal Safety*. Churchill Livingstone, USA, 2005.
- 49 Rose KD, Croissant PD, Parliament CF et al. *Neurosurgery* 1990; **26**(5): 880-882
- 50 Burnham BE. *Plast Reconstr Surg* 1995; **95**(1): 213
- 51 German K, Kumar U, Blackford HN. *Br J Urol* 1995; **76**(4): 518
- 52 Carden SM, Good WV, Carden PA et al. *Clin Experiment Ophthalmol* 2002; **30**(4): 303-304
- 53 Manoharan A, Gemmell R, Hartwell T. *Am J Hematol* 2006; **81**(9): 676-683
- 54 Legnani C, Frascaro M, Guazzaloca G et al. *Arzneim Forsch* 1993; **43**(2): 119-122
- 55 Kiesewetter H, Jung F, Jung EM et al. *Eur J Clin Pharmacol* 1993; **45**(4): 333-336
- 56 Kiesewetter H, Jung F, Jung EM et al. *Clin Investig* 1993; **71**(5): 383-386
- 57 Harenberg J, Giese C, Zimmermann R. *Atherosclerosis* 1988; **74**(3): 247-249
- 58 Ali M, Thomson M. *Prostaglandins Leukot Essent Fatty Acids* 1995; **53**(3): 211-212
- 59 Luley C, Lehmann-Leo W, Moller B et al. *Arzneim Forsch* 1986; **36**(4): 766-768
- 60 Scharbert G, Kalb ML, Duris M et al. *Anesth Analg* 2007; **105**(5): 1214-1218
- 61 Jain RC. *Am J Clin Nutr* 1977; **30**(9): 1380-1381
- 62 Lawson LD. *FASEB J* 2007; **21**(6): A1126
- 63 Gadkari JV, Joshi VD. *J Postgrad Med* 1991; **37**(3): 128-131
- 64 Sunter W. *Pharm J* 1991; **246**: 722
- 65 Piscitelli SC, Burstein AH, Welden N et al. *Clin Infect Dis* 2002; **34**(2): 234-238
- 66 Hajda J, Rentsch KM, Gubler C et al. *Eur J Pharm Sci* 2010; **41**(5): 729-735
- 67 Duncan A, Mills J. *AIDS* 2013; **27**(8): 1361-1362
- 68 Kruth P, Prosi E, Fux R et al. *Ann Pharmacother* 2004; **38**(2): 257-260
- 69 Verma SK, Singh J, Khamessa R et al. *Indian J Med Res* 1993; **98**: 240-242
- 70 Bordia A, Verma SK, Srivastava KC. *Prostaglandins Leukot Essent Fatty Acids* 1997; **56**(5): 379-384
- 71 Lumb AB. *Thromb Haemost* 1994; **71**(1): 110-111
- 72 Srivastava KC. *Prostaglandins Leukot Essent Fatty Acids* 1989; **35**(3): 183-185
- 73 Lesho EP, Saullo L, Udvari-Nagy S. *Cleve Clin J Med* 2004; **71**(8): 651-656
- 74 Jiang X, Williams KM, Liauw WS et al. *Br J Clin Pharmacol* 2005; **59**(4): 425-432
- 75 Shalansky S, Lynd L, Richardson K et al. *Pharmacotherapy* 2007; **27**(9): 1237-1247
- 76 Young HY, Liao JC, Chang YS et al. *Am J Chin Med* 2006; **34**(4): 545-551
- 77 Granger AS. *Age Ageing* 2001; **30**(6): 523-525
- 78 Gregory PJ. *Ann Intern Med* 2001; **134**(4): 344
- 79 Kupiec T, Raj V. *J Anal Toxicol* 2005; **29**(7): 755-758
- 80 Bruhn JG. *Phytomedicine* 2003; **10**(4): 358
- 81 Chan AL, Leung HW, Wu JW et al. *J Altern Complement Med* 2011; **17**(6): 513-517
- 82 Bent S, Goldberg H, Padula A et al. *J Gen Intern Med* 2005; **20**(7): 657-661
- 83 Griffiths J, Jordon S, Pilon K. *Canadian Adverse Reaction Newsletter* 2004; **14**(1): 2-3
- 84 Pedroso JL, Henriques Aquino CC, Escórcio Bezerra ML et al. *Neurologist* 2011; **17**(2): 89-90
- 85 Kellermann AJ, Kloft C. *Pharmacotherapy* 2011; **31**(5): 490-502
- 86 Vellas B, Coley N, Ousset PJ et al. *Lancet Neurol* 2012; **11**(10): 851-859
- 87 Schubert SR. *Consultant* 2013; **53**(6): 420-426
- 88 DeLoughery TG, Kaye JA, Morris CD et al. *Blood* 2002; **100**(11): Abstract #3809
- 89 Gardner CD, Zehnder JL, Rigby AJ et al. *Blood Coagul Fibrinolysis* 2007; **18**(8): 787-793
- 90 Wolf HR. *Drugs R D* 2006; **7**(3): 163-172
- 91 Aruna D, Naidu MU. *Br J Clin Pharmacol* 2007; **63**(3): 333-338
- 92 Kim HS, Kim GY, Yeo CW et al. *Br J Clin Pharmacol* 2014; **77**(5): 821-830
- 93 Darnborough S. *Menopause Int* 2012; **18**(3): 116-117
- 94 Kim BH, Kim KP, Lim KS et al. *Clin Ther* 2010; **32**(2): 380-390
- 95 Lu WJ, Huang JD, Lai ML. *J Clin Pharmacol* 2006; **46**(6): 628-634
- 96 Hong JM, Shin DH, Lim YA et al. *Thromb Res* 2013; **131**(4): e147-e153
- 97 Engelsen J, Nielsen JD, Winther K. *Thromb Haemost* 2002; **87**(6): 1075-1076
- 98 Lai CF, Chang CC, Fu CH et al. *Pharmacotherapy* 2002; **22**(10): 1326
- 99 Zhang XY, Zhou DF, Su JM et al. *J Clin Psychopharmacol* 2001; **21**(1): 85-88
- 100 Zhang XY, Zhou DF, Zhang PY et al. *J Clin Psychiatry* 2001; **62**(11): 878-883
- 101 Atmaca M, Tezcan E, Kuloglu M et al. *Psychiatry Clin Neurosci* 2005; **59**(6): 652-656
- 102 Doruk A, Uzun O, Ozsahin A. *Int Clin Psychopharmacol* 2008; **23**(4): 223-237
- 103 Blonk M, Colbers A, Poirters A et al. *Antimicrob Agents Chemother* 2012; **56**(10): 5070-5075

- 104 Wiegman DJ, Brinkman K, Franssen EJ. *AIDS* 2009; **23**(9): 1184-1185
- 105 Markowitz JS, Donovan JL, Lindsay DeVane C et al. *J Clin Psychopharmacol* 2003; **23**(6): 576-581
- 106 Zuo XC, Zhang BK, Jia SJ et al. *Eur J Clin Pharmacol* 2010; **66**(5): 503-509
- 107 Uchida S, Yamada H, Li XD et al. *J Clin Pharmacol* 2006; **46**(11): 1290-1298
- 108 Robertson SM, Davey RT, Voell J et al. *Curr Med Res Opin* 2008; **24**(2): 591-599
- 109 Zadoyan G, Rokitta D, Klement S et al. *Eur J Clin Pharmacol* 2012; **68**(5): 553-560
- 110 Kudolo GB, Wang W, Javors M et al. *Clin Nutr* 2006; **25**(4): 606-616
- 111 Personal communication from trial author Kudolo GB, 29 February 2008.
- 112 Wang W, Javors M, Blodgett J et al. *Diabetes* 2007; **56**(Suppl 1): A560
- 113 Smith M, Lin KM, Zheng MD. *Clin Pharmacol Ther* 2001; **69**(2): P86, Abstract #P113-89
- 114 Yoshioka M, Ohnishi N, Koishi T et al. *Biol Pharm Bull* 2004; **27**(12): 2006-2009
- 115 Yin OQ, Tomlinson B, Wayne MM et al. *Pharmacogenetics* 2004; **14**(12): 841-850
- 116 Guo CX, Pei Q, Yin JY et al. *Xenobiotica* 2012; **42**(8): 784-790
- 117 Dai LL, Fan L, Wu HZ et al. *Xenobiotica* 2013; **43**(10): 862-867
- 118 Fan L, Mao XQ, Tao GY et al. *Xenobiotica* 2009; **39**(3): 249-254
- 119 Chan E. *Biol Neonate* 1993; **63**(4): 201-208
- 120 Gurley BJ, Swain A, Hubbard MA et al. *Clin Pharmacol Ther* 2008; **83**(1): 61-69
- 121 Golden EB, Lam PY, Kardosh A et al. *Blood* 2009; **113**(23): 5927-5937
- 122 Bannerman B, Xu L, Jones M et al. *Cancer Chemother Pharmacol* 2011; **68**(5): 1145-1154
- 123 Alemdaroglu NC, Dietz U, Wolffram S et al. *Biopharm Drug Dispos* 2008; **29**(6): 335-348
- 124 Vischini G, Niscola P, Stefoni A et al. *Am J Kidney Dis* 2011; **58**(2): 329
- 125 Hegazy SK. *Br J Pharm Res* 2014; **4**(3): 289-300
- 126 Werba JP, Giroli M, Cavalca V et al. *Ann Intern Med* 2008; **149**(4): 286-287
- 127 Ge J, Tan BX, Chen Y et al. *J Mol Med* 2011; **89**(6): 595-602
- 128 Taylor JR, Wilt VM. *Ann Pharmacother* 1999; **33**(4): 426-428
- 129 Wolkerstorfer H. *MMW* 1966; **108**(8): 438-441
- 130 Jaurisch U, Landers E, Schmidt R et al. *Med Welt* 1969; **27**: 1547-1552
- 131 Tankanow R, Tamer HR, Streetman DS et al. *J Clin Pharmacol* 2003; **43**(6): 637-642
- 132 Iwamoto M, Ishizaki T, Sato T. *Planta Med* 1981; **42**(1): 1-16
- 133 Schmidt U, Kuhn U, Ploch M et al. *Phytomedicine* 1994; **1**(1): 17-24
- 134 Zick SM, Vautaux BM, Gillespie B et al. *Eur J Heart Fail* 2009; **11**(10): 990-999
- 135 Dalli E, Colomer E, Tormos MC et al. *Phytomedicine* 2011; **18**(8-9): 769-775
- 136 Walker AF, Marakis G, Simpson E. *Br J Gen Pract* 2006; **56**(527): 437-443
- 137 Shanmugasundaram ER, Rajeswari G, Baskaran K et al. *J Ethnopharmacol* 1990; **30**(3): 281-294
- 138 Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K et al. *J Ethnopharmacol* 1990; **30**(3): 295-300
- 139 Sobenin IA, Nedosugova LV, Filatova LV et al. *Acta Diabetol* 2008; **45**(1): 1-6
- 140 Almeida JC, Grimsley EW. *Ann Intern Med* 1996; **125**(11): 940-941
- 141 Cartledge A, Rutherford J. Rapid response (electronic letter), *BMJ* 12 Feb 2001. Available from bmj.com/cgi/eletters/322/7279/139#12643, downloaded 21/2/02.
- 142 Herberg KW, Winter U. 2nd International Congress on Phytomedicine, Munich, September 11-14, 1996, Abstract P-77.
- 143 Herberg KW. *Blutalkohol* 1993; **30**(2): 96-105
- 144 Schelosky L, Raffauf C, Jendroska K et al. *J Neurol Neurosurg Psychiatry* 1995; **58**(5): 639-640
- 145 Meseguer E, Taboada R, Sanchez V et al. *Mov Disord* 2002; **17**(1): 195-196
- 146 Noldner M, Chatterjee SS. *Phytomedicine* 1999; **6**(4): 285-286
- 147 Boerner RJ, Klement S. *Wien Med Wochenschr* 2004; **154**(21-22): 508-510
- 48 Yamamoto M, Tamura Y, Kuashima K et al. Cited in: Han KH, Choe SC, Kim HS et al. *Am J Chin Med* 1998; **26**(2): 199-209
- 149 Caron MF, Hotsko AL, Robertson S et al. *Ann Pharmacother* 2002; **36**(5): 758-763
- 150 Cherdrungsi P, Rungroeng K. Cited in: Buettner C, Yeh GY, Phillips RS et al. *Ann Pharmacother* 2006; **40**(1): 83-95
- 151 Park BJ, Lee YJ, Lee HR et al. *Korean J Fam Med* 2012; **33**(4): 190-196
- 152 Vuksan V, Sung MK, Sievenpiper JL et al. *Nutr Metab Cardiovasc Dis* 2008; **18**(1): 46-56
- 153 Kim NR, Kim JH, Kim CY. *J Ginseng Res* 2010; **34**(3): 237-245
- 154 Han KH, Choe SC, Kim HS et al. *Am J Chin Med* 1998; **26**(2): 199-209
- 155 Chung IM, Lim JW, Pyun WB et al. *J Ginseng Res* 2010; **34**(3): 212-218
- 156 Rhee MY, Kim YS, Bae JH et al. *J Altern Complement Med* 2011; **17**(1): 45-49
- 157 Lee JH, Park HJ. *J Ginseng Res* 1998; **22**(3): 173-180
- 158 Lee JH, Kim SH. *Korean J Nutr* 1995; **28**(9): 862-871
- 159 Shin KS, Lee JJ, Kim YI et al. *J Ginseng Res* 2007; **31**(2): 109-116
- 160 Janetzky K, Morreale AP. *Am J Health Syst Pharm* 1997; **54**(6): 692-693
- 161 Jiang X, Williams KM, Liauw WS et al. *Br J Clin Pharmacol* 2004; **57**(5): 592-599
- 162 Lee SH, Ahn YM, Ahn SY et al. *J Altern Complement Med* 2008; **14**(6): 715-721
- 163 Lee YH, Lee BK, Choi YJ et al. *Int J Cardiol* 2010; **145**(2): 275-276
- 164 Shao J, Jia L. *Trends Pharmacol Sci* 2013; **34**(2): 85-86
- 165 Bilgi N, Bell K, Ananthakrishnan AN et al. *Ann Pharmacother* 2010; **44**(5): 926-928
- 166 Mateo-Carrasco H, Gálvez-Contreras MC, Fernández-Ginés FD et al. *Drug Metabol Drug Interact* 2012; **27**(3): 171-175
- 167 Sotaniemi EA, Haapakoski E, Rautio A. *Diabetes Care* 1995; **18**(10): 1373-1375
- 168 Reeds DN, Patterson BW, Okunade A et al. *Diabetes Care* 2011; **34**(5): 1071-1076
- 169 Okuda H, Yoshida R. *Proceedings of the Third International Ginseng Symposium*. Seoul, Korea. Korea Ginseng Research Institute, September 8-10, 1980, pp 53-57.
- 170 Ma SW, Benzie IF, Chu TT et al. *Diabetes Obes Metab* 2008; **10**(11): 1125-1127
- 171 Tetsutani T, Yamamura M, Yamaguchi T et al. *Ginseng Rev* 2000; **28**: 44-47
- 172 Jones BD, Runikis AM. *J Clin Psychopharmacol* 1987; **7**(3): 201-202
- 173 Shader RI, Greenblatt DJ. *J Clin Psychopharmacol* 1988; **8**(4): 235
- 174 Shader RI, Greenblatt DJ. *J Clin Psychopharmacol* 1985; **5**(2): 65
- 175 Malati CY, Robertson SM, Hunt JD et al. *J Clin Pharmacol* 2012; **52**(6): 932-939
- 176 Gillis CN. *Biochem Pharmacol* 1997; **54**(1): 1-8
- 177 Kim HJ, Woo DS, Lee G et al. *Br J Urol* 1998; **82**(5): 744-748
- 178 *ESCOPE Monographs: The Scientific Foundation for Herbal Medicinal Products*, 2nd Edn. ESCOP, European Scientific Cooperative on Phytotherapy, Exeter, 2003.
- 179 Stormer FC, Reistad R, Alexander J. *Food Chem Toxicol* 1993; **31**(4): 303-312
- 180 Cheng CJ, Chen YH, Chau T et al. *Support Care Cancer* 2004; **12**(11): 810-812
- 181 Sigurjonsdottir HA, Franzson L, Manhem K et al. *J Hum Hypertens* 2001; **15**(8): 549-552
- 182 Sigurjonsdottir HA, Manhem K, Axelsson M et al. *J Hum Hypertens* 2003; **17**(2): 125-131
- 183 Sigurjonsdottir HA, Ragnarsson J, Franzson L et al. *J Hum Hypertens* 1995; **9**(5): 345-348
- 184 Sobieszczyk P, Borlaug BA, Gornik HL et al. *Clin Sci* 2010; **119**(10): 437-442
- 185 Ferrari P, Sansonnens A, Dick B et al. *Hypertension* 2001; **38**(6): 1330-1336
- 186 van Gelderen CE, Bijlsma JA, van Dokkum W et al. *Hum Exp Toxicol* 2000; **19**(8): 434-439
- 187 Brouwers AJ, van der Meulen J. *Ned Tijdschr Geneesk* 2001; **145**(15): 744-747
- 188 Yoshino T, Yanagawa T, Watanabe K. *J Altern Complement Med* 2014; **20**(6): 516-520
- 189 Iida R, Otsuka Y, Matsumoto K et al. *Clin Exp Nephrol* 2006; **10**(2): 131-135
- 190 Maeda Y, Inaba N, Aoyagi M et al. *Intern Med* 2008; **47**(14): 1345-1348
- 191 Stewart PM, Burra P, Shackleton CH et al. *J Clin Endocrinol Metab* 1993; **76**(3): 748-751
- 192 Kageyama Y, Suzuki H, Saruta T. *J Endocrinol* 1992; **135**(1): 147-152
- 193 Mackenzie MA, Hoefnagels WH, Jansen RW et al. *J Clin Endocrinol Metab* 1990; **70**(6): 1637-1643
- 194 Stewart PM, Wallace AM, Valentino R et al. *Lancet* 1987; **330**(8563): 821-824
- 195 Epstein MT, Espiner EA, Donald RA et al. *J Clin Endocrinol Metab* 1978; **47**(2): 397-400
- 196 Mattarello MJ, Benedini S, Fiore C et al. *Steroids* 2006; **71**(5): 403-408
- 197 Miglieri EG. *Steroids* 1995; **60**(1): 52-58
- 198 Forslund T, Fyhrquist F, Froseth B et al. *J Intern Med* 1989; **225**(2): 95-99
- 199 Stewart PM, Wallace AM, Atherden SM et al. *Clin Sci* 1990; **78**(1): 49-54
- 200 van Uum SH, Walker BR, Hermus AR et al. *Clin Sci* 2002; **102**(2): 203-211
- 201 Armanini D, Nacamulli D, Francini-Pesenti F et al. *Steroids* 2005; **70**(8): 538-542
- 202 Kasuya Y, Yokokawa A, Takashima S et al. *Steroids* 2005; **70**(2): 117-125
- 203 Kasuya Y, Yokokawa A, Hamura K et al. *Steroids* 2005; **70**(12): 811-816
- 204 Teelucksingh S, Mackie AD, Burt D et al. *Lancet* 1990; **335**(8697): 1060-1063
- 205 Chen MF, Shimada F, Kato H et al. *Endocrinol Jpn* 1991; **38**(2): 167-174
- 206 Conti M, Frey FJ, Escher G et al. *Nephrol Dial Transplant* 1994; **9**(11): 1622-1628
- 207 Shintani S, Murase H, Tsukagoshi H et al. *Eur Neurol* 1992; **32**(1): 44-51
- 208 Bernardi M, d-Intimo PE, Trevisani F et al. *Life Sci* 1994; **55**(11): 863-872
- 209 Harada T, Ohtaki E, Mitsu K et al. *Cardiology* 2002; **98**(4): 218

- 210 Armanini D, Castello R, Scaroni C et al. *Eur J Obstet Gynecol Reprod Biol* 2007; **131**(1): 61-67
- 211 Kurisu S, Inoue I, Kawagoe T et al. *J Am Geriatr Soc* 2008; **56**(8): 1579-1581
- 212 Heidemann HT, Kreuzfelder E. *Klin Wochenschr* 1983; **61**(6): 303-305
- 213 Chataway SJ, Mumford CJ, Ironside JW. *Postgrad Med J* 1997; **73**(863): 593-594
- 214 Folkersen L, Knudsen NA, Teglbjaerg PS. *Ugeskr Laeger* 1996; **158**(51): 7420-7421
- 215 Famularo G, Corsi FM, Giacanelli M. *Acad Emerg Med* 1999; **6**(9): 960-964
- 216 Nielsen I, Pedersen RS. *Lancet* 1984; **323**(8389): 1305
- 217 Conn JW, Rovner DR, Cohen EL. *JAMA* 1968; **205**(7): 492-496
- 218 Sontia B, Mooney J, Gaudet L et al. *J Clin Hypertens* 2008; **10**(2): 153-157
- 219 Hukkanen J, Ukkola O, Savolainen MJ. *Blood Press* 2009; **18**(4): 192-195
- 220 Jiao Z, Shi XJ, Li ZD et al. *Br J Clin Pharmacol* 2009; **68**(1): 47-60
- 221 Tu JH, He YJ, Chen Y et al. *Eur J Clin Pharmacol* 2010; **66**(8): 805-810
- 222 Tu JH, Hu DL, Dai LL et al. *Xenobiotica* 2010; **40**(6): 393-399
- 223 Liapina LA, Koval'chuk GA. *Izv Akad Nauk Ser Biol* 1993; (4): 625-628
- 224 Velussi M, Cernigoi AM, de Monte A et al. *J Hepatol* 1997; **26**(4): 871-879
- 225 Jose MA, Abraham A, Narmadha MP. *J Pharmacol Pharmacother* 2011; **2**(4): 287-289
- 226 Hussain SA. *J Med Food* 2007; **10**(3): 543-547
- 227 Huseini HF, Larijani B, Heshmat R et al. *Phytother Res* 2006; **20**(12): 1036-1039
- 228 Taher MA, Atia YA, Amin MK. *Iraqi J Pharm Sci* 2010; **19**(2): 11-18
- 229 Hashemi SJ, Hajjani E, Sardabi EH. *Hep Mon* 2009; **9**(4): 265-270
- 230 Deng YQ, Fan XF, Li JP. *Chin J Integr Med* 2005; **11**(2): 117-122
- 231 Han Y, Guo D, Chen Y et al. *Eur J Clin Pharmacol* 2009; **65**(6): 585-591
- 232 Rajnarayana K, Reddy MS, Vidyasagar J et al. *Arzneim Forsch* 2004; **54**(2): 109-113
- 233 Fuhr U, Beckmann-Knopp S, Jetter A et al. *Planta Med* 2007; **73**(14): 1429-1435
- 234 Repalle SS, Yamsani SK, Gannu R et al. *Acta Pharm Sci* 2009; **51**(1): 15-20
- 235 Han Y, Guo D, Chen Y et al. *Xenobiotica* 2009; **39**(9): 694-699
- 236 Nowack R, Nowak B. *Nephrol Dial Transplant* 2005; **20**(11): 2554-2556
- 237 Hurrell RF, Reddy M, Cook JD. *Br J Nutr* 1999; **81**(4): 289-295
- 238 Fleming DJ, Jacques PF, Dallal GE et al. *Am J Clin Nutr* 1998; **67**(4): 722-733
- 239 Li J, Wang R, Xiao C. *J Med Food* 2014; **17**(4): 472-478
- 240 Samman S, Sandstrom B, Toft MB et al. *Am J Clin Nutr* 2001; **73**(3): 607-612
- 241 Tuntipipat S, Judprasong K, Zeder C et al. *J Nutr* 2006; **136**(12): 2970-2974
- 242 Olivares M, Pizarro F, Hertrampf E et al. *Nutrition* 2007; **23**(4): 296-300
- 243 Kubota K, Sakurai T, Nakazato K et al. *Nippon Ronen Igakkai Zasshi* 1990; **27**(5): 555-558
- 244 Mitamura T, Kitazono M, Yoshimura O et al. *Nippon Sanka Fujinka Gakkaai Zasshi* 1989; **41**(6): 688-694
- 245 Prystai EA, Kies CV, Driskell JA. *Nutr Res* 1999; **19**(2): 167-177
- 246 Schlesier K, Kuhn B, Kiehnopf M et al. *Food Res Int* 2012; **46**(2): 522-527
- 247 Mennen L, Hirvonen T, Arnault N et al. *Eur J Clin Nutr* 2007; **61**(10): 1174-1179
- 248 Imai K, Nakachi K. *BMJ* 1995; **310**(6981): 693-696
- 249 Ullmann U, Haller J, Bakker GC et al. *Phytomedicine* 2005; **12**(6-7): 410-415
- 250 Hutchinson C, Bomford A, Geissler CA. *Eur J Clin Nutr* 2010; **64**(10): 1239-1241
- 251 Cheema P, El-Mefty O, Jazieh AR. *J Intern Med* 2001; **250**(2): 167-169
- 252 Geavlete P, Multescu R, Geavlete B. *Ther Adv Urol* 2011; **3**(4): 193-198
- 253 Yue QY, Jansson K. *J Am Geriatr Soc* 2001; **310**(4): 838
- 254 Villanueva S, González J. *Bol Asoc Med PR* 2009; **101**(3): 48-50
- 255 Li R, Guo W, Fu Z et al. *Can J Physiol Pharmacol* 2012; **90**(7): 941-945
- 256 Xin HW, Wu XC, Li Q et al. *Br J Clin Pharmacol* 2007; **64**(4): 469-475
- 257 Jiang W, Wang X, Xu X et al. *Int J Clin Pharmacol Ther* 2010; **48**(3): 224-229
- 258 Jiang W, Wang X, Kong L. *Immunopharmacol Immunotoxicol* 2010; **32**(1): 177-178
- 259 Xin HW, Wu XC, Li Q et al. *Br J Clin Pharmacol* 2009; **67**(5): 541-546
- 260 Ko KM, Ip SP, Poon MK et al. *Planta Med* 1995; **61**(2): 134-137
- 261 Lu H, Liu GT. *Zhongguo Yao Li Xue Bao* 1990; **11**(4): 331-335
- 262 John A, Schmider J, Brockmoller J et al. *J Clin Psychopharmacol* 2002; **22**(1): 46-54
- 263 Australian Therapeutic Goods Administration. Media Release, March 2000.
- 264 Breckenridge A. Message from Committee on Safety of Medicines, 29 February 2000. Medicines Control Agency, London.
- 265 Henney JE. *JAMA* 2000; **283**(13): 1679
- 266 Burstein AH, Horton RL, Dunn T et al. *Clin Pharmacol Ther* 2000; **68**(6): 605-612
- 267 *Drug Safety Update* Volume 1, Issue 4, November 2007, p 7. Available from www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm. Accessed 18 April 2008.
- 268 Wang LS, Zhu B, Abd El-Aty AM et al. *J Clin Pharmacol* 2004; **44**(6): 577-581
- 269 Wang Z, Hamman MA, Huang SM et al. *Clin Pharmacol Ther* 2002; **71**(6): 414-420
- 270 Dresser GK, Schwarz UI, Wilkinson GR et al. *Clin Pharmacol Ther* 2003; **73**(1): 41-50
- 271 Lau WC, Gurbel PA, Carville DG et al. *J Am Coll Cardiol* 2007; **49**(9, Suppl 1): 343A-344A
- 272 Lau WC, Welch TD, Shields TA et al. *J Am Coll Cardiol* 2010; **55**(10, Suppl 1): A171.E1600
- 273 Lau WC, Welch TD, Shields T et al. *J Cardiovasc Pharmacol* 2011; **57**(1): 86-93
- 274 Trana C, Toth G, Wijns W et al. *J Cardiovasc Transl Res* 2013; **6**(3): 411-414
- 275 Fitzgerald DJ, Maree A. *Hematology Am Soc Hematol Educ Program* 2007; **2007**: 114-120
- 276 Maurer A, John A, Bauer S et al. *Eur J Clin Pharmacol* 1999; **55**(3): A22
- 277 Yue QY, Bergquist C, Gerden B. *Lancet* 2000; **355**(9203): 576-577
- 278 Barnes J, Anderson LA, Phillipson JD. *J Pharm Pharmacol* 2001; **53**(5): 583-600
- 279 Uygun Bayramci O, Kalkay MN, Oskay Bozkaya E et al. *Turk J Gastroenterol* 2011; **22**(1): 115
- 280 Mueller SC, Majcher-Peszynska J, Uehleke B et al. *Eur J Clin Pharmacol* 2006; **62**(1): 29-36
- 281 Arold G, Donath F, Maurer A et al. *Planta Med* 2005; **71**(4): 331-337
- 282 Markowitz JS, Donovan JL, DeVane CL et al. *JAMA* 2003; **290**(11): 1500-1504
- 283 Wang Z, Gorski JC, Hamman MA et al. *Clin Pharmacol Ther* 2001; **70**(4): 317-326
- 284 Mueller SC, Majcher-Peszynska J, Mundkowski RG et al. *Eur J Clin Pharmacol* 2009; **65**(1): 81-87
- 285 Kawaguchi A, Ohmori M, Tsuruoka S et al. *Br J Clin Pharmacol* 2004; **58**(4): 403-410
- 286 Wang XD, Li JL, Lu Y et al. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; **852**(1-2): 534-544
- 287 Tannergren C, Engman H, Knutson L et al. *Clin Pharmacol Ther* 2004; **75**(4): 298-309
- 288 Mathijssen RH, Verweij J, de Bruijn P et al. *J Natl Cancer Inst* 2002; **94**(16): 1247-1249
- 289 Mansky PJ, Straus SE. *J Natl Cancer Inst* 2002; **94**(16): 1187-1188
- 290 Smith PF, Bullock JM, Booker BM et al. *Blood* 2004; **104**(4): 1229-1230
- 291 Frye RF, Fitzgerald SM, Lagattuta TF et al. *Clin Pharmacol Ther* 2004; **76**(4): 323-329
- 292 Van Strater AC, Bogers JP. *Int Clin Psychopharmacol* 2012; **27**(2): 121-124
- 293 John A, Brockmoller J, Bauer S et al. *Clin Pharmacol Ther* 1999; **66**(4): 338-345
- 294 Durr D, Stieger B, Kullak-Ublick GA et al. *Clin Pharmacol Ther* 2000; **68**(6): 598-604
- 295 Mueller SC, Uehleke B, Woehling H et al. *Clin Pharmacol Ther* 2004; **75**(6): 546-557
- 296 Goey AK, Meijerman I, Rosing H et al. *Clin Pharmacokinetics* 2014; **53**(1): 103-110
- 297 Lundahl A, Hedeland M, Bondesson U et al. *Eur J Pharm Sci* 2009; **36**(4-5): 433-443
- 298 Anon. *Reactions Weekly* 2011; **1336**: 22
- 299 de Maat MMR, Hoetelmans RMW, Mathot RAA et al. *AIDS* 2001; **15**(3): 420-421
- 300 Piscitelli SC, Burstein AH, Chait D et al. *Lancet* 2000; **355**(9203): 547-548
- 301 Xu H, Williams KM, Liauw WS et al. *Br J Pharmacol* 2008; **153**(7): 1579-1586
- 302 Fan L, Zhou G, Guo D et al. *Clin Pharmacokinetics* 2011; **50**(9): 605-611
- 303 Bon S, Hartmann K, Kuhn M. *Schweiz Apoth* 1999; **16**: 535-536
- 304 Ahmed SM, Banner NR, Dubrey SW. *J Heart Lung Transplant* 2001; **20**(7): 795
- 305 Ruschitzka F, Meier PJ, Turina M et al. *Lancet* 2000; **355**(9203): 548-549
- 306 Mai I, Kruger H, Budde K et al. *Int J Clin Pharmacol Ther* 2000; **38**(10): 500-502
- 307 Karliova M, Treichel U, Malago M et al. *J Hepatol* 2000; **33**(5): 853-855
- 308 Rey JM, Walter G. *Med J Aust* 1998; **169**(11-12): 583-586
- 309 Barone GW, Gurley BJ, Ketel BL et al. *Transplantation* 2001; **71**(2): 239-241
- 310 Barone GW, Gurley BJ, Ketel BL et al. *Ann Pharmacother* 2000; **34**(9): 1013-1016
- 311 Moschella C, Jaber BL. *Am J Kidney Dis* 2001; **38**(5): 1105-1107
- 312 Beer AM, Ostermann T. *Med Klin* 2001; **96**(8): 480-483
- 313 Breidenbach T, Kliem V, Burg M et al. *Transplantation* 2000; **69**(10): 2229-2230
- 314 Mai I, Bauer S, Perloff ES et al. *Clin Pharmacol Ther* 2004; **76**(4): 330-340
- 315 Bolley R, Zulke C, Kammerl M et al. *Transplantation* 2002; **73**(6): 1009
- 316 Mai I, Stormer E, Bauer S et al. *Nephrol Dial Transplant* 2003; **18**(4): 819-822
- 317 Hebert MF, Park JM, Chen YL et al. *J Clin Pharmacol* 2004; **44**(1): 89-94
- 318 Portoles A, Terleira A, Calvo A et al. *J Clin Pharmacol* 2006; **46**(10): 1188-1194
- 319 Peltoniemi MA, Saari TI, Hagelberg NM et al. *Fundam Clin Pharmacol* 2012; **26**(6): 743-750

- 320 Eich-Hochli D, Oppliger R, Golay KP et al. *Pharmacopsychiatry* 2003; **36**(1): 35-37
- 321 Niederhofer H. *Med Hypotheses* 2007; **68**(5): 1189
- 322 Galeotti N, Farzad M, Bianchi E et al. *J Pharmacol Sci* 2014; **124**(4): 409-417
- 323 Wang LS, Zhou G, Zhu B et al. *Clin Pharmacol Ther* 2004; **75**(3): 191-197
- 324 Information from the MPA (Medical Products Agency, Sweden) and the MCA (Medicines Control Agency, UK), 2000-2002.
- 325 Schwarz UI, Buschel B, Kirch W. *Br J Clin Pharmacol* 2003; **55**(1): 112-113
- 326 *Drug Safety Update* March 2014 Volume 7, Issue 8: A2. Available from <http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392869>. Accessed June 2014.
- 327 Murphy PA, Kern SE, Stanczyk FZ et al. *Contraception* 2005; **71**(6): 402-408
- 328 Hall SD, Wang Z, Huang SM et al. *Clin Pharmacol Ther* 2003; **74**(6): 525-535
- 329 Pfrunder A, Schiesser M, Gerber S et al. *Br J Clin Pharmacol* 2003; **56**(6): 683-690
- 330 Will-Shahab L, Bauer S, Kunter U et al. *Eur J Clin Pharmacol* 2009; **65**(3): 287-294
- 331 Murphy P, Bellows B, Kern S. *Contraception* 2010; **82**(2): 191
- 332 Fogle RH, Murphy PA, Westhoff CL et al. *Contraception* 2006; **74**(3): 245-248
- 333 Nieminen TH, Hagelberg NM, Saari TI et al. *Eur J Pain* 2010; **14**(8): 854-859
- 334 Gordon JB. *Am Fam Phys* 1998; **57**(5): 950, 953
- 335 Dermott K. *Clinical Psychiatry News* 1998; **26**(3): 28
- 336 Barbenel DM, Yusuf B, O'Shea D et al. *J Psychopharmacol* 2000; **14**(1): 84-86
- 337 Lantz MS, Buchalter E, Giambanco V. *J Geriatr Psychiatry Neurol* 1999; **12**(1): 7-10
- 338 Prost N, Tichadou L, Rodor F et al. *Presse Med* 2000; **29**(23): 1285-1286
- 339 Waksman JC, Heard K, Jolliff H et al. *Clin Toxicol* 2000; **38**(5): 521
- 340 Andren L, Andreasson A, Eggertsen R. *Eur J Clin Pharmacol* 2007; **63**(10): 913-916
- 341 Sugimoto K, Ohmori M, Tsuruoka S et al. *Clin Pharmacol Ther* 2001; **70**(6): 518-524
- 342 Gordon RY, Becker DJ, Rader DJ. *Am J Med* 2009; **122**(2): e1-e2
- 343 Eggertsen R, Andreasson A, Andren L. *Scand J Prim Health Care* 2007; **25**(3): 154-159
- 344 Schwarz UI, Hanso H, Oertel R et al. *Clin Pharmacol Ther* 2007; **81**(5): 669-678
- 345 Nebel A, Schneider BJ, Baker RK et al. *Ann Pharmacother* 1999; **33**(4): 502
- 346 Morimoto T, Kotegawa T, Tsutsumi K et al. *J Clin Pharmacol* 2004; **44**(1): 95-101
- 347 Rengelshausen J, Banfield M, Riedel KD et al. *Clin Pharmacol Ther* 2005; **78**(1): 25-33
- 348 Hojo Y, Echizenya M, Ohkubo T et al. *J Clin Pharm Ther* 2011; **36**(6): 711-715
- 349 Rossander L, Hallberg L, Bjorn-Rasmussen E. *Am J Clin Nutr* 1979; **32**(12): 2484-2489
- 350 Disler PB, Lynch SR, Charlton RW et al. *Gut* 1975; **16**(3): 193-200
- 351 Brune M, Rossander L, Hallberg L. *Eur J Clin Nutr* 1989; **43**(8): 547-557
- 352 Derman D, Sayers M, Lynch SR et al. *Br J Nutr* 1977; **38**(2): 261-269
- 353 Hallberg L, Rossander L. *Hum Nutr Appl Nutr* 1982; **36**(2): 116-123
- 354 Chung KT, Wong TY, Wei CI et al. *Crit Rev Food Sci Nutr* 1998; **38**(6): 421-464
- 355 Morck TA, Lynch SR, Cook JD. *Am J Clin Nutr* 1983; **37**(3): 416-420
- 356 Layrisse M, Garcia-Casal MN, Solano L et al. *J Nutr* 2000; **130**(9): 2195-2159. Erratum in: *J Nutr* 2000; **130**(12): 3106
- 357 Thankachan P, Walczyk T, Muthayya S et al. *Am J Clin Nutr* 2008; **87**(4): 881-886
- 358 Nelson M, Poulter J. *J Hum Nutr Diet* 2004; **17**(1): 43-54
- 359 Gabrielli GB, De Sandre G. *Haematologica* 1995; **80**(6): 518-520
- 360 Mahlknecht U, Weidmann E, Seipelt G. *Haematologica* 2001; **86**(5): 559
- 361 Kaltwasser JP, Werner E, Schalk K et al. *Gut* 1998; **43**(5): 699-704
- 362 Ganji V, Kies CV. *Plant Foods Hum Nutr* 1994; **46**(3): 267-276
- 363 Juan H, Terhaag B, Cong Z et al. *Eur J Clin Pharmacol* 2007; **63**(7): 663-668
- 364 USP Drug Information, US Pharmacopeia Patient Leaflet, Valerian (Oral). Rockville: The United States Pharmacopeial Convention, 1998.
- 365 Herberg KW. *Therapiewoche* 1994; **44**(12): 704-713
- 366 Carrasco MC, Vallejo JR, Pardo-de-Santayana M et al. *Phytother Res* 2009; **23**(12): 1795-1796
- 367 Donovan JL, DeVane CL, Chavin KD et al. *Drug Metab Dispos* 2004; **32**(12): 1333-1336
- 368 Krivoy N, Pavlotzky E, Chrubasik S et al. *Planta Med* 2001; **67**(3): 209-212
- 369 Personal communication from trial author Yu KS, 2 February 2010.
- 370 Makino T, Hishida A, Goda Y et al. *Nat Med* 2008; **62**(3): 294-299
- 371 Product information for Cranberry Classic juice drink. Available from www.oceanspray.com.au. Accessed November 2009.
- 372 Dasgupta A, Wu S, Actor J et al. *Am J Clin Pathol* 2003; **119**(2): 298-303
- 373 Warshafsky S, Kamer RS, Sivak SL. *Ann Intern Med* 1993; **119**(7 Pt 1): 599-605
- 374 Lawson LD, Wang JZ, Papadimitriou D. *Planta Med* 2001; **67**(1): 13-18
- 375 De Smet PA, Floor-Schreuderling A, Bouvy ML et al. *Curr Drug Metab* 2008; **9**(10): 1055-1062
- 376 Leistner E, Drewke C. *J Nat Prod* 2010; **73**(1): 86-92
- 377 Kajiyama Y, Fujii K, Takeuchi H et al. *Pediatrics* 2002; **109**(2): 325-327
- 378 Hasegawa S, Oda Y, Ichiyama T et al. *Pediatr Neurol* 2006; **35**(4): 275-276
- 379 Arenz A, Klein M, Fiehe K et al. *Planta Med* 1996; **62**(6): 548-551
- 380 Kuenick C. *Dtsch Apoth Ztg* 2010; **150**(5): 60-61
- 381 Gaus W, Westendorf J, Diebow R. et al. *Methods Inf Med* 2005; **44**(5): 697-703
- 382 DeKosky ST, Williamson JD, Fitzpatrick AL et al. *JAMA* 2008; **300**(19): 2253-2262
- 383 Kim TE, Kim BH, Kim J et al. *Clin Ther* 2009; **31**(10): 2249-2257
- 384 Shah JJ, Kuhn DJ, Orlowski RZ. *Blood* 2009; **113**(23): 5695-5696
- 385 Henning SM, Niu Y, Liu Y et al. *J Nutr Biochem* 2005; **16**(10): 610-616
- 386 Kageyama Y, Suzuki H, Saruta T. *Endocrinol Jpn* 1991; **38**(1): 103-108
- 387 Haslam E, Lilley TH. *Crit Rev Food Sci Nutr* 1988; **27**(1): 1-40
- 388 Price ML, Butler LG. *J Agric Food Chem* 1977; **25**(6): 1268-1273
- 389 Halstead CW, Lee S, Khoo CS et al. *J Pharm Biomed Anal* 2007; **45**(1): 30-37
- 390 Zhu M, Chen XS, Wang KX. *Chromatographia* 2007; **66**(1-2): 125-128
- 391 Ang CYW, Hu L, Heinze TM et al. *J Agric Food Chem* 2004; **52**(20): 6156-6164
- 392 MediHerb Research Laboratories, 2004.
- 393 Tomlinson B, Hu M, Lee VW. *Mol Nutr Food Res* 2008; **52**(7): 799-809
- 394 Lynch SR. *Nutr Rev* 1997; **55**(4): 102-110
- 395 Gilooly M, Bothwell TH, Charlton RW et al. *Br J Nutr* 1984; **51**(1): 37-46